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Abstract 
The role of the hypothalamic preoptic area (POA) in arousal state regulation has been studied since the 
early 20th century. Since then, the POA has been shown to modulate arousal in both natural (sleep and 
wake) as well as drug-induced (anesthetic-induced unconsciousness) states. While the POA is most 
known for its role in sleep promotion, populations of wake-promoting neurons within the region have also 
been identified. However, the complexity and molecular heterogeneity of the POA has made 
distinguishing these two populations difficult. Though multiple lines of evidence demonstrate that general 
anesthetics modulate the activity of the POA, the region’s heterogeneity has also made it challenging to 
determine whether the same neurons involved in sleep/wake regulation also modulate arousal in 
response to general anesthetics. While a number of studies show that sleep-promoting POA neurons are 
activated by various anesthetics, recent work suggests this is not universal to all arousal-regulating POA 
neurons. We hypothesized that the POA’s broad neuronal diversity could mask convergent roles of a 
subset of neurons in regulating both arousal and anesthesia. 
In this dissertation, we utilize a neuropeptide, tachykinin 1 (Tac1), as a molecular marker for arousal state-
regulating POA neurons and show using EEG/EMG recordings that chemogenetic activation of these POA 
Tac1 neurons strongly promotes wakefulness over both NREM and REM sleep, consolidating the wake 
state for hours. Additionally, actigraphy and video recordings demonstrate that POA Tac1 activation 
increases locomotor activity, with no evidence of enhanced anxiety. We also show that activation of this 
same population stabilizes the wake state against both isoflurane- and sevoflurane-induced 
unconsciousness, producing a partial resistance to entering isoflurane anesthesia and a more 
pronounced ability to exit both isoflurane and sevoflurane hypnosis. Furthermore, activation of POA Tac1 
neurons promotes resistance throughout prolonged exposures to isoflurane on both the population and 
individual level, further supporting their arousal-promoting role. Together, these results demonstrate that 
POA Tac1 neurons can potently reinforce arousal against both endogenous and drug-induced states of 
unconsciousness, identifying a subpopulation within the POA that may be shared between the circuits 
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A ROLE FOR TACHYKININ 1 PREOPTIC NEURONS IN NATURAL AND ANESTHETIC-
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Max B. Kelz 
 
The role of the hypothalamic preoptic area (POA) in arousal state regulation has been 
studied since the early 20th century. Since then, the POA has been shown to modulate 
arousal in both natural (sleep and wake) as well as drug-induced (anesthetic-induced 
unconsciousness) states. While the POA is most known for its role in sleep promotion, 
populations of wake-promoting neurons within the region have also been identified. 
However, the complexity and molecular heterogeneity of the POA has made 
distinguishing these two populations difficult. Though multiple lines of evidence 
demonstrate that general anesthetics modulate the activity of the POA, the region’s 
heterogeneity has also made it challenging to determine whether the same neurons 
involved in sleep/wake regulation also modulate arousal in response to general 
anesthetics. While a number of studies show that sleep-promoting POA neurons are 
activated by various anesthetics, recent work suggests this is not universal to all arousal-
regulating POA neurons. We hypothesized that the POA’s broad neuronal diversity could 
mask convergent roles of a subset of neurons in regulating both arousal and anesthesia. 
In this dissertation, we utilize a neuropeptide, tachykinin 1 (Tac1), as a molecular marker 
for arousal state-regulating POA neurons and show using EEG/EMG recordings that 
chemogenetic activation of these POA Tac1 neurons strongly promotes wakefulness 
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over both NREM and REM sleep, consolidating the wake state for hours. Additionally, 
actigraphy and video recordings demonstrate that POA Tac1 activation increases 
locomotor activity, with no evidence of enhanced anxiety. We also show that activation 
of this same population stabilizes the wake state against both isoflurane- and 
sevoflurane-induced unconsciousness, producing a partial resistance to entering 
isoflurane anesthesia and a more pronounced ability to exit both isoflurane and 
sevoflurane hypnosis. Furthermore, activation of POA Tac1 neurons promotes 
resistance throughout prolonged exposures to isoflurane on both the population and 
individual level, further supporting their arousal-promoting role. Together, these results 
demonstrate that POA Tac1 neurons can potently reinforce arousal against both 
endogenous and drug-induced states of unconsciousness, identifying a subpopulation 
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CHAPTER 1 – General Introduction 
	
Regulating the timing and stability of the states of consciousness and unconsciousness 
is critical for an individual’s health and survival. A complete and extended period of sleep 
deprivation results in death, while insufficient sleep impairs cognitive performance, 
increases the risk of obesity and cardiovascular disease, and impairs immune system 
function, among other effects (Everson, 1993; Taheri, 2006; Vgontzas et al., 2009; 
Besedovsky et al., 2012). On the other hand, excessive sleep is also associated with 
pathology, including obesity, diabetes, heart disease, and increased mortality (Gallicchio 
and Kalesan, 2009; Buxton and Marcelli, 2010; Cappuccio et al., 2010). Thus, regulating 
arousal to ensure the proper timing and amount of sleep is crucial for normal 
physiological function. While essential for survival, sleep confers a period of extreme 
vulnerability, as the individual is unconscious and unaware of its surroundings. Thus, the 
ability to rapidly transition from sleep to wake is crucial in order to defend against 
external threats and respond to the surrounding environment. Given the importance of 
these states, an understanding of how the brain properly regulates arousal state is 
critical. While many neural circuits involved in sleep and wake have been identified over 
the last century, our understanding of how the brain regulates arousal state is far from 
complete.  
 
Arousal State Regulation of Sleep and Wake 
Prior to the 20th century, sleep was thought of as a passive process, caused not by 
specific neural circuits but rather by reduced sensory input that led to low levels of brain 
activity. This thinking shifted in the early 20th century during a viral pandemic of 
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encephalitis lethargica. In some of the earliest examinations into the neurobiology of 
sleep and wake regulation, neurologist Constantin von Economo noted lesions in the 
posterior hypothalamus of his patients with excessive sleepiness, while other patients 
exhibiting severe insomnia tended to have lesions in the anterior hypothalamus. This led 
him to propose the existence of a “sleep center” in the anterior hypothalamus and a 
corresponding “wake center” in the posterior hypothalamus that act in opposition to 
regulate arousal (von Economo, 1930). Since these original findings, the existence of 
hypothalamic circuits involved in regulating arousal state has been repeatedly confirmed. 
Given the importance of properly regulating the states of sleep and wake, it is not 
altogether surprising that work over the past few decades has also established that 
arousal state regulation is not solely localized to the hypothalamus, but is instead a 
highly redundant system distributed widely across the brain.  
 
Arousal-Promoting Nuclei 
Populations of wake-promoting neurons are now known to exist across the neuroaxis. 
As a group, these neurons show increased activity during wakefulness (and sometimes 
REM sleep) with little or no activity during NREM sleep. An increasing number of brain 
regions are now suspected of playing a role in promoting the wake state, though the 
degree to which they do so varies and is continually being refined. These populations 
are grouped according to anatomical location as well as neurotransmitter expression, 
and are discussed below: 
Locus Coeruleus (LC): The LC is the largest source of norepinephrine in the brain, 
projecting widely to the cortex, hippocampus, amygdala, thalamus, hypothalamus, basal 
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forebrain, and other subcortical regions. LC neurons are classified as wake-active, with 
firing rates at their highest during wake, decreasing during NREM sleep, and virtually 
absent during REM sleep (Aston-Jones and Bloom, 1981a). Optogenetic activation of 
these neurons causes rapid transitions from sleep to wake in mice, and norepinephrine 
agonists also increase wakefulness. Conversely, optogenetic inhibition of LC neurons 
mildly reduces wakefulness (Carter et al., 2010). In particular, LC neurons are thought to 
be essential for arousal in response to novel stimuli, salient stimuli and stressors (Aston-
Jones and Bloom, 1981b; Aston-Jones and Cohen, 2005).  
Raphe Nuclei (RN): The RN consists of the dorsal raphe and median raphe nuclei and is 
the major source of another monoamine, serotonin (5-HT). Similar to the LC, it shows 
arousal state-dependent activity and innervates regions across the brain, including the 
cortex, basal forebrain, hypothalamus, thalamus, amygdala, and insula (Weissbourd et 
al., 2014). Optogenetic stimulation of 5-HT RN neurons destabilizes NREM sleep and 
doubles the amount of wake (Ito et al., 2013). Furthermore, drugs that increase levels of 
5-HT, such as SSRIs, are known to increase wakefulness (Wichniak et al., 2017).  
Tuberomammillary Nucleus (TMN): The TMN, located in the posterior hypothalamus, is 
the sole source of histamine in the brain (Watanabe et al., 1983). Like the other 
monoaminergic regions listed above, TMN neurons exhibit highest activity during wake, 
lower activity during NREM sleep, and no activity during REM sleep (John et al., 2004; 
Takahashi et al., 2006). Chemogenetic activation of TMN neurons increases wake and 
locomotion (Yu et al., 2015), while histamine receptor antagonists, like those found in 
allergy medications, have a sedative effect (Parmentier et al., 2016).  
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Ventral Tegmental Area (VTA): While the dopaminergic neurons of the VTA are 
classically associated with the reward circuitry, recent work suggests they are also 
involved in sleep/wake regulation. While these neurons don’t display the same state-
dependent activity as the regions listed above (Miller et al., 1983; Trulson and Preussler, 
1984), chemogenetic inhibition of dopaminergic VTA neurons increases sleep under 
both baseline conditions and conditions of high motivation, such as food-seeking (Eban-
Rothschild et al., 2016). On the other hand, optogenetic activation of these neurons 
increases wakefulness, producing rapid transitions from sleep to wake (Oishi et al., 
2017; Sun et al., 2017). More recent work has also implicated glutamatergic/nitrergic 
(NOS1) VTA neurons in promoting wakefulness (Yu et al., 2019).  
Ventral Periaqueductal Gray (vPAG): Another population of dopaminergic wake-
promoting neurons exists in the vPAG, a region just lateral to the RN. The vPAG projects 
to the basal forebrain, prefrontal cortex, thalamus, hypothalamus, RN, and LC (Lu et al., 
2006). These neurons express c-Fos, an immediate early gene associated with neuronal 
activity, during periods of wake. Additionally, lesions in this region result in a roughly 
20% decrease in wake (Lu et al., 2006).  
Basal Forebrain (BF): The BF contains populations of cholinergic neurons and 
GABAergic neurons, both known to be wake-promoting. The cholinergic neurons 
innervate the cortex, playing an important role in cortical arousal, as well as neighboring 
hypothalamic neurons and the hippocampus. Similar to many other arousal-promoting 
regions, these neurons show highest activity during wake and low activity during NREM 
sleep, but are also active during REM sleep (Xu et al., 2015). Chemogenetic activation 
of cholinergic BF neurons destabilizes NREM sleep and reduces slow wave EEG 
activity, without affecting the total amount of wake (Anaclet et al., 2015; Chen et al., 
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2016). Optogenetic activation of the cholinergic BF neurons transitions mice from NREM 
sleep to wake and prolongs periods of wakefulness (Ozen Irmak and De Lecea, 2014; 
Xu et al., 2015), though these differing results may be due to the method of activation 
used. Inhibition of the cholinergic BF neurons, both optogenetically and 
chemogenetically, increase slow wave EEG activity and stabilize NREM sleep, but again 
have no significant effect on total amount of sleep or wake (Shi et al., 2015; Chen et al., 
2016). Thus, the cholinergic BF neurons appear to be important for cortical arousal, but 
perhaps not necessary for wakefulness.  
GABAergic neurons in the BF outnumber cholinergic neurons 2:1 (Sarter and Bruno, 
2002), yet their role in arousal state regulation is just beginning to be explored. Like their 
cholinergic neighbors, a subpopulation of GABAergic BF neurons shows maximum 
activity during periods of wake (Duque et al., 2000; Hassani et al., 2009). They innervate 
the thalamus, cortex, and many hypothalamic nuclei important in arousal state regulation 
(Anaclet et al., 2015). Chemogenetic activation of this population strongly promotes 
wakefulness, while inhibition leads to increased NREM sleep (Anaclet et al., 2015). The 
GABAergic BF neurons are a highly heterogeneous population however (Hassani et al., 
2009; Xu et al., 2015), and more work is required to untangle exactly which 
subpopulations are important in wake promotion. 
Pedunculopontine (PPT) and Laterodorsal Tegmental (LDT) Nuclei: The PPT and LDT 
also contain populations of wake-promoting cholinergic neurons. Similar to the 
cholinergic BF neurons, the cholinergic PPT and LDT neurons project to many 
subcortical regions, including the thalamus. However, unlike the BF, they provide very 
sparse innervation of the cortex (Satoh and Fibiger, 1986; Woolf and Butcher, 1986). 
These neurons show highest activity during wake and REM sleep (Boucetta et al., 
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2014). Chemogenetic activation of cholinergic PPT neurons decreases slow wave EEG 
activity during NREM sleep (Kroeger et al., 2017), but it remains unknown whether this 
population is capable of promoting wake in addition to suppressing cortical slow wave 
activity. In another similarity to the BF, recent work has also identified a role for 
GABAergic and glutamatergic PPT neurons in wake promotion. Chemogenetic activation 
of glutamatergic PPT neurons significantly increases wake, while chemogenetic 
activation of GABAergic PPT neurons shortens latency to sleep onset and reduces REM 
sleep (Kroeger et al., 2017).  
Supramammillary Nucleus (SuM): A population of wake-promoting glutamatergic 
neurons in the SuM were recently uncovered (Pedersen et al., 2017). These neurons 
project to the cortex, the basal forebrain, the hippocampus, and regions of the upper 
brainstem, including the LC, RN, and parabrachial nucleus (Swanson, 1982; Saper, 
1985; Vertes, 1992; Liu and Mihailoff, 1999; Pan and McNaughton, 2004). 
Chemogenetic activation of glutamatergic SuM neurons strongly promotes consolidated 
periods of wakefulness, while chemogenetic inhibition destabilizes the wake state and 
increases NREM sleep. Additionally, chemogenetic activation of a subpopulation of the 
glutamatergic SuM neurons that co-express Nos1 also promotes wakefulness, though 
inhibition has no effect on sleep-wake regulation (Pedersen et al., 2017). 
Parabrachial Nucleus (PB): The PB contains glutamatergic neurons that heavily 
innervate the BF as well as the lateral hypothalamus and amygdala (Fulwiler and Saper, 
1984; Fuller et al., 2011; Qiu et al., 2016). Lesioning or inhibiting Vglut2 signaling from 
these neurons reduces wake and increases slow wave EEG activity during NREM sleep 
(Fuller et al., 2011; Kaur et al., 2013). PB neurons are activated in response to hypoxia, 
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pain, and cold, suggesting they are important for arousal in response to external stimuli 
(Kaur et al., 2013).  
Lateral Hypothalamus (LH): The LH contains two known populations of wake-regulating 
neurons: orexinergic neurons (also known as hypocretin) and GABAergic neurons (De 
Lecea et al., 1998; Sakurai et al., 1998; Venner et al., 2016). Orexinergic neurons 
project widely to wake-promoting brain regions as well as the thalamus and cortex, and 
show highest activity during active periods (Peyron et al., 1998; Lee et al., 2005; 
Mileykovskiy et al., 2005), suggesting they promote wakefulness by exciting other 
arousal-promoting regions. These neurons are important in stabilizing and maintaining 
wakefulness, as both optogenetic and chemogenetic activation of this population 
increases wake (Adamantidis et al., 2007; Sasaki et al., 2011), while lesions result in 
much shorter bouts of wakefulness, with increased transitions between sleep and wake 
(Branch et al., 2016). This is most commonly observed in narcolepsy, a sleep disorder 
caused by loss of the orexinergic LH neurons (Chemelli et al., 1999; Lin et al., 1999).   
While the orexinergic neurons are the most well known population of wake-promoting LH 
neurons, recent work has also identified a population of wake-promoting GABAergic LH 
neurons. These neurons project to sleep promoting brain regions, and increase 
wakefulness following chemogenetic activation (Venner et al., 2016).  
 
Sleep-Promoting Nuclei 
As with the wake-promoting nuclei of the brain, sleep-promoting neurons were originally 
thought to be constricted to the anterior hypothalamus but are now known to exist 
throughout the brain. These neurons show increased activity during NREM (and 
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sometimes REM) sleep, and reduced activity during wake. While they typically are 
GABAergic, populations of sleep-promoting neurons that utilize neuropeptides are now 
known to exist as well.  
Preoptic Area (POA): The role of the POA in arousal state regulation is discussed in 
more detail in a later section of this chapter, so only a brief overview will be covered 
here. While sleep-active neurons are scattered across the POA, a dense cluster of these 
neurons exists in the ventrolateral preoptic area (VLPO) (Sherin et al., 1996, 1998; 
Szymusiak et al., 1998). This small nucleus of NREM-active GABAergic/galaninergic 
neurons promotes sleep when activated. Conversely, lesions of the VLPO reduce sleep 
(Lu et al., 2000). Another population of sleep-active GABAergic neurons is found in the 
median preoptic nucleus (MnPO). These neurons show increases in activity just prior to 
the onset of sleep (Suntsova et al., 2007), suggesting a role in sleep initiation. 
Additionally, both VLPO and MnPO neurons show higher activity in response to sleep 
deprivation, prior to recovery sleep, suggesting a role in tracking sleep debt (Alam et al., 
2014).  
Basal Forebrain (BF): While the BF is typically associated with wake promotion, 
populations of sleep-promoting neurons also exist in the region. These neurons are 
mostly GABAergic and are most active immediately prior to sleep onset and throughout 
sleep (Hassani et al., 2009). In particular, the somatostatin-expressing GABAergic BF 
neurons appear to play a role in promoting sleep. Optogenetic activation increases 
NREM sleep, likely by inhibiting neighboring wake-active BF neurons (Xu et al., 2015).  
Supraoptic Nucleus (SON): Sleep-promoting neurons in the SON, a small region located 
directly dorsal to the optic nerve, were identified in 2019 (Jiang-Xie et al., 2019). These 
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neurons are peptidergic neuroendocrine cells, expressing galanin, arginine vasopressin, 
and prodynorphin, all neuropeptides that have been previously linked to sleep regulation 
(Greco et al., 2008; Trudel and Bourque, 2010; Kroeger et al., 2018). SON neurons 
project to many other sleep and arousal centers, including the LH, TMN, SUM, septum, 
anterior thalamus, vPAG, VTA, and PPT/LDT (Jiang-Xie et al., 2019). Both optogenetic 
and chemogenetic activation promotes NREM sleep, while ablation of this population 
fragmented and decreased time spent asleep. These SON neurons are activated by 
sleep pressure rather than sleep itself, suggesting a role in sleep homeostasis (Jiang-Xie 
et al., 2019). 
Parafacial Zone (PZ): The PZ, located dorsal and lateral to the 7th nerve in the medulla, 
was one of the first non-hypothalamic sleep-promoting regions to be identified. 
Chemogenetic activation of GABAergic PZ neurons promotes extended, consolidated 
periods of NREM sleep, even overcoming the wake-promoting effects of 
psychostimulants, while inhibition or lesion of these neurons decreases NREM sleep 
(Anaclet et al., 2012, 2014, 2017). These neurons are NREM-active, with highest activity 
immediately prior to NREM onset as well as throughout NREM sleep (Alam et al., 2018). 
They project to and inhibit the wake-promoting PB neurons, providing a likely 
mechanism by which they promote sleep (Anaclet et al., 2014).  
Cortical nNOS Neurons: While much of the cortex is wake-active, a population of cortical 
GABAergic interneurons that also express neuronal nitric oxide synthase (nNOS) are 
instead active during both normal NREM sleep and recovery NREM sleep following 
sleep deprivation (Gerashchenko et al., 2008). Deleting nNOS results in shorter bouts of 
NREM sleep and reduced total sleep time, as well as an impaired response to sleep 
deprivation (Morairty et al., 2013). As these neurons project throughout the cortex, they 
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are hypothesized to play a role in synchronizing EEG activity across the cortex (Kilduff et 
al., 2011), though this remains to be tested. 
Lhx6 Ventral Zona Incerta (VZI) Neurons: Lhx6-expressing neurons in the VZI are a 
subpopulation of GABAergic neurons that project to and inhibit the wake-active 
orexinergic and GABAergic neurons of the LH. They also project to the VTA, RN, vPAG, 
and amygdala and are in turn innervated by those same regions as well as the 
cholinergic BF and PPT neurons. The Lhx6 VZI neurons are activated by sleep 
pressure, and deletion of Lhx6 from the VZI and surrounding hypothalamus decreases 
slow wave EEG activity during NREM sleep as well as total time spent asleep. 
Furthermore, chemogenetic activation increased both NREM and REM sleep, while 
inhibition reduced time spent in NREM and REM sleep (Liu et al., 2017).  
Flip-Flop Switch Model of Sleep/Wake Regulation 
Given that numerous sleep- and wake-promoting regions exist throughout the brain, a 
major focus is on understanding how these nuclei work together to regulate arousal 
state. One hypothesis builds on von Economo’s model of sleep and wake centers acting 
in opposition to each other. This theory, commonly called the flip-flop switch model, 
posits that the neural circuits regulating sleep and arousal mutually inhibit each other via 
reciprocal inhibitory connections. In this way, the arousal state regulating circuitry forms 
a flip-flop switch in which only the sleep- or wake-promoting neurons are active at any 
given time. Any small increase in activity on one side of the switch enhances the 
inhibition on the opposite circuit, further disinhibiting and reinforcing their own activity. 
This results in a bistable feedback loop that allows for rapid transitions between sleep 
and wake without an extended period of time in an intermediate state. A switch of this 
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sort also stabilizes the states of sleep and wake, preventing one state from 
inappropriately intruding into the other (Saper et al., 2001).  
This theory is supported by numerous studies showing reciprocal connections between 
members of the sleep- and wake-promoting circuits. Many of the arousal-promoting 
nuclei mentioned earlier project to one or more of the sleep-promoting nuclei and inhibit 
the neurons (Figure 1.1). For example, putative sleep-active VLPO neurons receive 
projections from the LC, TMN, and RN (Chou et al., 2002) and are inhibited by 
norepinephrine and serotonin (Gallopin et al., 2000). Conversely, VLPO sends inhibitory 
projections throughout the wake-promoting circuit, providing widespread inhibition to 
promote a transition to the sleep state (Sherin et al., 1998; Steininger et al., 2001). As 
previously mentioned, this is true for other sleep-promoting neurons as well (Figure 1.2). 
The Lhx6 VZI neurons innervate and inhibit the LH, VTA, RN, and vPAG and are in turn 
innervated by these same regions (Liu et al., 2017). The PZ sends inhibitory projections 
to the wake-promoting PB (Anaclet et al., 2012, 2014) and is innervated by the 
orexinergic LH (Peyron et al., 1998), though whether the PZ is reciprocally connected to 
these two regions has not yet been investigated. In addition, many wake-promoting 
regions are interconnected, potentially serving to reinforce the wake state when active 
(Vertes and Martin, 1988; Cullinan and Záborszky, 1991; Semba, 2000; Zaborszky and 
Duque, 2000). Furthermore, activation of GABAergic VLPO projections to the TMN 
promotes sleep (Chung et al., 2017), while activation of wake-promoting GABAergic LH 
neurons decreases c-Fos in VLPO (Venner et al., 2016). However, as is clear from the 
number of new sleep- and wake-promoting regions uncovered in the last decade alone, 
this is far from a complete picture of arousal state regulation. As more sleep- or wake-




Arousal State Regulation of Anesthetic-Induced Unconsciousness 
While sleep is a universal, natural form of unconsciousness, unconsciousness also 
occurs under general anesthesia. However, despite the use of anesthetics for over 170 
years and in over 300 million surgeries annually (Weiser et al., 2016), the precise 
molecular and neuronal mechanisms underlying their hypnotic actions remain poorly 
understood. This is especially concerning given that each year a small but significant 
number of patients experience abnormal arousal state transitions in response to general 
anesthesia. These patients may regain consciousness during surgery (Sebel et al., 
2004; Mashour and Avidan, 2015; Sanders et al., 2017) or exhibit delayed emergence 
from the anesthetic state (Mesa et al., 2000). Thus, understanding the mechanisms by 
which general anesthetics alter the arousal state of an organism, producing a state of 
unconsciousness, is an important medical question to ultimately reduce or prevent these 
inappropriate arousal state transitions from occurring. Additionally, insights into the 
mechanisms of anesthetic-induced unconsciousness will have important implications for 
our understanding of the neural basis of consciousness and natural arousal state 
regulation itself, as well as disorders of consciousness such as coma and sleep 
disorders.  
Early Theories of Anesthetic-Induced Unconsciousness 
The molecular mechanisms of anesthetic-induced unconsciousness remain unknown 
due in part to the transient interactions and promiscuous number of general anesthetic 
binding partners (Eckenhoff, 2001; Eckenhoff et al., 2002), yet all produce an apparently 
similar behavioral endpoint. Early theories built on the observation that the potency of an 
anesthetic was directly proportional to its solubility in olive oil. In attempts to propose a 
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unifying mechanism underlying the main components of anesthesia, theories based on 
this correlation hypothesized that anesthetic effects were caused by solubilization of 
anesthetic molecules inside the lipid bilayer of neuronal cell membranes, mutating the 
cell membrane and resulting in neuronal malfunction. However, these theories were 
proven unlikely in the 1980s when a diverse range of anesthetics were shown to inhibit 
firefly luciferase in a completely lipid-free preparation (Franks and Lieb, 1984). Following 
this demonstration that anesthetics could directly bind to and affect the activity of 
proteins, research increasingly focused on ion channels as potential molecular targets of 
anesthetic agents. However, to date there is no single class of ion channels known to be 
universally affected by all anesthetics (Rudolph and Antkowiak, 2004). 
While a variety of ion channels are affected by anesthetics, the net effect of anesthetic 
binding is the hyperpolarization of resting membrane potentials, enhancement of 
inhibitory neurotransmission, and inhibition of excitatory neurotransmission. Most volatile 
and intravenous anesthetics inhibit excitation, and ultimately decrease neuronal activity, 
by prolonging the open time of GABAA receptors. Volatile anesthetics also inhibit 
excitation by acting presynaptically at glutamatergic synapses to decrease glutamate 
release. Nonhalogenated inhaled anesthetics (xenon, nitrous oxide, and cyclopropane), 
as well as the intravenous dissociative anesthetic ketamine, inhibit excitation 
postsynaptically by blocking NMDA glutamate receptors (Rudolph and Antkowiak, 2004; 
Hemmings Jr, 2010).  
With the knowledge that anesthetics act on a diverse range of ion channels yet all 
generally lead to enhanced inhibition (via inhibition of excitatory neurotransmission or 
increase in inhibitory neurotransmission), more recent research has examined the 
hypothesis that anesthetics may exert their effects not by acting at identical molecular 
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targets, but rather by differentially affecting neurons in a common neural pathway. 
However, because these receptors are widely expressed throughout the brain, 
identifying the exact neural circuits critical for producing a state of anesthesia has been 
difficult.  
The Shared Circuit Hypothesis: Sleep/Wake Circuitry as a Mediator of Anesthetic-
Induced Unconsciousness 
One target that has emerged as a likely mediator of anesthetic hypnosis is the neural 
circuitry governing sleep and arousal discussed earlier. Although sleep and anesthesia 
are undoubtedly two distinct states, they share a number of similar traits (Lydic and 
Biebuyck, 1994). For example, both NREM sleep and anesthetic hypnosis show EEG 
patterns that include spindles and slow waves (Murphy et al., 2011). Neuroimaging 
studies have also shown reduced activity in brain regions involved in arousal (Alkire et 
al., 2000; Vahle-hinz et al., 2001; Detsch et al., 2002) as well as cortical regions involved 
in association and integration in both states of unconsciousness (Fiset et al., 1999; 
Franks, 2008).  
In addition to these phenotypic similarities, multiple lines of evidence demonstrate a 
functional relationship between sleep and anesthetic hypnosis. Sleep deprivation 
reduces the amount of anesthetic required to enter the hypnotic state (Tung et al., 2002), 
while administration of barbiturates during the waking phase results in a shorter duration 
of hypnosis (Einon et al., 1976). Furthermore, administration of select anesthetics for 
prolonged periods does not incur new sleep debt and may actually relieve preexisting 
sleep debt (Tung et al., 2004; Nelson et al., 2010; Pal et al., 2011; Pick et al., 2011). 
These findings have led to what is known as the “shared circuitry hypothesis” of 
anesthesia, which posits that anesthetics exert their hypnotic effects by acting on the 
15	
	
neural circuitry that regulates endogenous sleep and wake. More specifically, this theory 
hypothesizes that anesthetics cause unconsciousness via activation of sleep-promoting 
populations and/or inhibition of wake-promoting populations (Lydic and Biebuyck, 1994). 
Investigations of anesthetic action on many of the sleep and wake nodes support this 
hypothesis, summarized below. 
Administration of anesthetics decreases neural activity in wake nodes and increases 
activity in sleep nodes: Anesthetic alteration of neuronal activity is observed in many 
regions of the sleep/wake circuitry. GABAergic VTA neurons are inhibited by halothane, 
ketamine, and chloral hydrate (Lee et al., 2001), and chloral hydrate is also known to 
decrease the firing of DR neurons (Heym et al., 1984). Isoflurane, sevoflurane, 
pentobarbital, and propofol all decrease c-Fos expression in orexinergic LH neurons 
(Kelz et al., 2008; Zecharia et al., 2009; Zhang et al., 2012). The LC is inhibited by 
isoflurane, propofol, and dexmedetomidine (Nelson et al., 2003; Gompf et al., 2009; 
Zecharia et al., 2009). Histamine levels in the anterior hypothalamus decrease during 
halothane anesthesia (Mammoto et al., 1997) and propofol decreases c-Fos expression 
in the TMN (Nelson et al., 2002), suggesting an inhibition of histaminergic TMN neurons 
by at least these two anesthetics. Activity of PB neurons is suppressed during propofol 
and isoflurane anesthesia, and returns upon emergence (Luo et al., 2018). Finally, SON 
neurons are activated by isoflurane, propofol, ketamine, and dexmedetomidine (Jiang-
Xie et al., 2019). However, a correlative modulation of one region’s activity by an 
anesthetic does not mean it is actively involved in producing anesthetic hypnosis, 
especially in the case of wake-promoting regions, as anesthetics are known to produce 
widespread inhibition across the brain. To more strongly support a region’s involvement, 
its ability to modulate sensitivity to the anesthetic(s) is critical. 
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Inhibition of wake nodes/activation of sleep nodes increases sensitivity to anesthesia: 
Inhibition or lesion of wake-active areas has indeed been shown to enhance sensitivity 
to a number of general anesthetics. Lesioning the dorsal raphe, but not the median 
raphe, increases sensitivity to halothane by 25% (Roizen et al., 1978; Ma and Leung, 
2006). Inhibiting the VTA extends the duration of LORR under both halothane and 
pentobarbital (Ma and Leung, 2006). In the hypothalamus, loss of orexinergic LH 
neurons delays emergence from isoflurane and sevoflurane anesthesia (Kelz et al., 
2008) but not halothane anesthesia (Gompf et al., 2009). In the LC, mice lacking 
norepinephrine are hypersensitive to halothane, isoflurane, and sevoflurane (Hu et al., 
2012). However, LC lesions decreased duration of ketamine anesthesia, suggesting it 
may actually facilitate ketamine-induced unconsciousness (Kushikata et al., 2011). 
Lesions of cholinergic BF neurons increase the duration of LORR under propofol and 
pentobarbital but not halothane anesthesia (Leung et al., 2011). In regards to sleep 
promoting regions, activation of SON neurons that promote sleep also prolong 
emergence from isoflurane anesthesia (Jiang-Xie et al., 2019). Neurons in the POA are 
also capable of modulating anesthetic sensitivity, and will be discussed in more detail in 
the next section.  
Activation of wake nodes/inhibition of sleep nodes promotes resistance to anesthesia: 
Similarly, activation of wake-active areas has also been shown to modulate anesthetic 
sensitivity. Stimulation of the reticular formation in anesthetized cats produces EEG 
patterns that resemble those observed during wake (Moruzzi and Magoun, 1949). 
Activation of LC neurons induces cortical activation during isoflurane anesthesia (Vazey 
and Aston-Jones, 2014). It also increases the time to induction and decreases time to 
emerge from isoflurane anesthesia (Vazey and Aston-Jones, 2014). Brain-wide 
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administration of orexin-A reduces duration of LORR under propofol, barbiturates, and 
ketamine (Kushikata et al., 2003; Tose et al., 2009; Zecharia et al., 2009). Additionally, 
local infusion of orexin-A into the basal forebrain decreases time to emerge from 
sevoflurane, isoflurane, and propofol anesthesia (Dong et al., 2009; Zhang et al., 2012, 
2016). Beyond the orexin system, activation of GABAergic LH neurons produces cortical 
arousal and recovery of muscle tone (Herrera et al., 2015). Dopamine receptor agonists, 
specifically D1 agonists, induce behavioral arousal under continuous isoflurane 
anesthesia and decrease time to emerge from isoflurane as well (Solt et al., 2011; Taylor 
et al., 2013). Additionally, activation of dopaminergic VTA neurons during isoflurane 
anesthesia restores the righting reflex (Taylor et al., 2016). Finally, activation of PB 
neurons promotes emergence from isoflurane anesthesia but does not affect induction 
time (Muindi et al., 2016; Luo et al., 2018). In the sleep-promoting circuitry, inhibition of 
SON neurons increases time to emerge from isoflurane anesthesia without affecting 
induction time (Jiang-Xie et al., 2019).  
Though much work has been accomplished, the shared circuitry hypothesis is far from 
confirmed. The role of many arousal state-regulating regions, particularly more recently 
discovered areas, in modulating the anesthetic state have yet to be fully examined. It 
has been repeatedly demonstrated that specific anesthetics act on the sleep and arousal 
circuitry in distinct ways and at sometimes non-overlapping regions, requiring an 
investigation of multiple anesthetics in each region. Some regions also appear to be 
involved in only induction or emergence, as is the case with the orexinergic LH neurons, 
which are important for emerging from anesthetic hypnosis, but not for induction of 
hypnosis (Kelz et al., 2008; Dong et al., 2009; Gompf et al., 2009; Zhang et al., 2012, 
2016). Perhaps the biggest challenge facing investigations into this theory however, is 
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an incomplete understanding of the neural circuitry regulating sleep and wake. In no 
region is this arguably more clear than the POA.  
 
Arousal State Regulation By The POA 
Although the POA was one of the earliest studied regions in regards to sleep and wake 
regulation, it remains one of the most difficult to untangle. This region of the anterior 
hypothalamus consists of the following subregions: the medial preoptic area (MPO), 
lateral preoptic area (LPO), ventrolateral preoptic area (VLPO), and median preoptic 
area (MnPO). This section reviews the current understanding of the POA’s role in 
arousal state regulation of both natural and drug-induced forms of unconsciousness, 
including its molecular organization and connectivity to other known sleep and wake 
promoting regions. 
POA Regulation of Natural Arousal States 
Early studies found that broad activation of the POA results in the rapid onset of sleep 
(Sterman and Clemente, 1962), while lesions of the area significantly decrease sleep 
(McGinty and Sterman, 1968; John and Kumar, 1998; Lu et al., 2000). Later in vivo 
recordings revealed that the POA is much more heterogeneous than originally thought 
based on the early stimulation and lesion studies. In addition to sleep-active neurons, 
the POA contains wake-active and arousal state-indifferent neurons scattered among 
the sleep-active population (Kaitin, 1984; Szymusiak and McGinty, 1989). However, 
higher densities of sleep-active neurons are found in the VLPO and MnPO (Szymusiak 
et al., 1998; Takahashi et al., 2009). For this reason, the majority of the work focusing on 
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POA regulation of arousal state has focused on these two subregions, though a small 
number of more recent studies have investigated the LPO as well.  
VLPO: The VLPO is a small cluster of largely GABAergic neurons that are most active 
during NREM and REM sleep (Sherin et al., 1996; Szymusiak et al., 1998; Gong et al., 
2000, 2004; Alam et al., 2014). These GABAergic VLPO neurons also express galanin, 
an inhibitory neuropeptide (Sherin et al., 1998). VLPO neurons are not only sleep-active, 
they are also sleep-promoting. Chemogenetic and optogenetic activation of galaninergic 
VLPO neurons significantly increases NREM sleep (Kroeger et al., 2018). Similarly, 
another study shows that chemogenetic activation of GABAergic VLPO neurons 
promotes NREM sleep as well (Vanini et al., 2020). While the VLPO is typically 
associated with NREM sleep, a cluster of GABAergic/galaninergic neurons in the 
extended VLPO is active during REM sleep and reduces REM when lesioned (Lu et al., 
2002). 
VLPO activity correlates with sleep amount, with the average number of c-Fos-
expressing VLPO neurons increasing with more time spent asleep (Sherin et al., 1996). 
It was previously thought that VLPO had no role in sensing or responding to sleep 
pressure, as c-Fos levels were not increased unless animals experienced recovery sleep 
following sleep deprivation (Sherin et al., 1996; Gvilia et al., 2006). However, more 
recent studies found that the VLPO exhibits increased c-Fos expression and higher firing 
rates during sleep deprivation, prior to recovery sleep, suggesting at least a minor role 
for VLPO in sleep homeostasis as well (Gong et al., 2004; Alam et al., 2014). These may 
represent two distinct subpopulations within VLPO: one that promotes sleep in response 
to sleep pressure, and one that maintains sleep (Gallopin et al., 2005). 
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Investigations into the VLPO’s connectivity support the flip-flop switch theory of sleep 
regulation. As discussed earlier, the VLPO is reciprocally connected to many members 
of the arousal-promoting circuitry, including the cholinergic BF, LH, TMN, RN, PB, and 
LC (Sherin et al., 1998; Steininger et al., 2001; Chou et al., 2002; Yoshida et al., 2006). 
VLPO neurons with projections to the LH, RN and vPAG express c-Fos during sleep 
(Uschakov et al., 2006, 2009; Hsieh et al., 2011). GABAergic VLPO neurons are directly 
inhibited by acetylcholine, norepinephrine, and serotonin (Gallopin et al., 2000), 
providing a mechanism by which the wake-active centers can promote wakefulness. 
Additionally, GABA levels in the LC and RN are increased during sleep (Nitz and Siegel, 
1997b, 1997a) and galanin inhibits the TMN and LC (Schönrock et al., 1991; Pieribone 
et al., 1995). Furthermore, activation of the VLPO in ex vivo brain slices produces 
GABA-mediated inhibitory postsynaptic potentials in histaminergic TMN neurons (Yang 
and Hatton, 1997), supporting a role for GABAergic/galaninergic VLPO neurons in 
promoting sleep. Thus, not only are the VLPO and many wake-promoting regions 
reciprocally connected, they also mutually inhibit each other, providing support for the 
flip-flop switch theory of arousal regulation. 
While most of the work investigating the role of the VLPO in arousal state regulation has 
focused on the GABAergic/galaninergic neurons, other neuronal types exist within the 
region. Additional studies are needed to determine what role, if any, non-GABAergic 
VLPO neurons play in arousal state regulation, although a recent study found that 
activation of glutamatergic VLPO neurons increases wakefulness (Vanini et al., 2020).  
MnPO: Similar to VLPO, the MnPO consists largely of GABAergic neurons that are most 
active during NREM and REM sleep compared to baseline wake (Gong et al., 2000; 
McGinty et al., 2004; Alam et al., 2014). These neurons are also sleep-promoting, as 
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chemogenetic activation of the GABAergic MnPO promotes sleep (Vanini et al., 2020). 
However, unlike the VLPO, MnPO activity appears to correlate with sleep pressure 
rather than sleep amount (Suntsova et al., 2002). The number of c-Fos positive, GAD-
expressing MnPO neurons is highest following sleep deprivation but prior to recovery 
sleep (Gvilia et al., 2006). Additionally, sleep-active MnPO neurons exhibit increased 
firing rates as sleep pressure builds during sleep deprivation, ultimately firing twice as 
frequently after 2 hours of sleep deprivation compared to baseline sleep. This firing 
returns to baseline levels as the animal is allowed to sleep (Alam et al., 2014). Together, 
this suggests a role for the MnPO in tracking sleep debt and maintaining sleep 
homeostasis. 
The MnPO may contribute to sleep homeostasis via inhibition of numerous wake-
promoting regions. Like the VLPO, the MnPO is also reciprocally connected to many 
members of the arousal-promoting circuitry, including the cholinergic BF, LH, TMN, RN, 
PB, and LC (Steininger et al., 2001; Yoshida et al., 2006; Uschakov et al., 2007). MnPO 
neurons with projections to the RN and vPAG express c-Fos during sleep (Uschakov et 
al., 2009; Hsieh et al., 2011). Furthermore, activation of MnPO neurons suppresses 
activity in the wake-active LH, while inhibition of the MnPO had the opposite effect 
(Suntsova et al., 2007). Similarly, inhibition of MnPO neurons increases c-Fos in the 
orexinergic LH neurons and serotonergic RN neurons (Kumar et al., 2008), further 
suggesting functional inhibition of these two wake centers by the MnPO. 
Wider POA: Given that arousal state regulating neurons are known to exist throughout 
the POA, not just in the VLPO and MnPO, more recent studies have begun investigating 
the wider POA, including the LPO. Still, these studies have largely focused on the 
GABAergic/galaninergic population in the region. These populations project to many of 
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the same wake-promoting centers as VLPO and MnPO, including the LH and TMN 
(Saito et al., 2013; Chung et al., 2017). Activation of GABAergic POA projections to the 
LH directly inhibits orexinergic neurons in the area (Saito et al., 2013). Furthermore, 
optogenetic activation of GABAergic POA projections to the TMN promotes sleep, while 
inhibition promotes wake. However, optogenetic activation of GABAergic POA neurons 
or glutamatergic POA projections to TMN neurons promotes wakefulness, while 
activation of GABAergic POA projections to either the habenula or the dorsomedial 
hypothalamus have no effect on arousal state (Chung et al., 2017).  
Arousal state regulation in the wider POA is likely more variable than the VLPO or MnPO 
due to its increased heterogeneity. Recordings of 128 LPO neurons show that ~38% are 
wake/REM-active, ~43% are sleep-active, and ~19% are state-indifferent (Alam et al., 
2014). Activation of galaninergic LPO neurons promotes NREM sleep, while ablation of 
this population fragments NREM sleep during the active phase, increasing the number of 
transitions between the wake and NREM sleep states (Ma et al., 2019). This suggests 
that galaninergic LPO neurons are essential for consolidated sleep, but are sufficient, 
not necessary, for NREM sleep. In contrast to the MnPO and VLPO, sleep-active 
neurons in the LPO do not show increased activity in response to sleep deprivation 
(Alam et al., 2014), suggesting this population is not involved in sleep homeostasis. 
Adaptive Arousal State Regulation by the POA 
Multiple lines of evidence suggest the POA is capable of integrating diverse inputs, such 
as temperature and energy status, to produce the most appropriate arousal state 
response. Alterations in body temperature are known to correlate with arousal state. The 
onset of sleep coincides with a decline in body temperature, and entry into REM is 
accompanied by near total inhibition of thermoregulatory responses in many species 
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(Krueger and Takahashi, 1997). The POA is poised to be the link between sleep and 
thermoregulation, as the POA is known to contain thermosensitive and thermoregulatory 
neurons (Zhao et al., 2017; Ma et al., 2019), with many of the warm-sensitive POA 
neurons also exhibiting sleep-active firing, while cold-sensitive POA neurons show 
increased activity during wake (Alam et al., 1995, 1997). Further supporting this link is 
evidence that local warming of the broad POA or the GABAergic MPO neurons 
promotes sleep (Roberts and Robinson, 1969; Harding et al., 2018), while local cooling 
promotes wakefulness (Sakaguchi et al., 1979; McGinty and Szymusiak, 1990). 
Further investigations revealed that reactivation of MnPO or LPO neurons that were 
activated during recovery sleep produces drops in body temperature (Zhang et al., 
2015b). Additionally, chemogenetic activation of galaninergic VLPO neurons reduces 
core body temperature by 4-6°C (Kroeger et al., 2018). Furthermore, activation of those 
same neurons at warmer temperatures (29°C and 36°C) decreases latency to NREM 
and increases NREM duration compared to activation at 22°C (Kroeger et al., 2018). 
The extreme drop in body temperature resulting from galaninergic VLPO activation also 
suggests a role for the VLPO in torpor, another state of unconsciousness accompanied 
by hypothermia, decreased metabolism, and slow wave EEG activity.  
Finally, local administration of glucose in the VLPO activates VLPO neurons and 
promotes NREM sleep, providing a potential link between metabolism/energy status and 
arousal state regulation in the POA (Varin et al., 2015). 
POA Regulation of Arousal Under Anesthesia 
Because the VLPO and MnPO contain the highest densities of sleep-active neurons, the 
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majority of work investigating the role of the POA in anesthetic hypnosis has focused on 
these two regions, particularly the VLPO.  
VLPO: Exposure to hypnotic doses of all anesthetics except for ketamine increases c-
Fos expression in VLPO (Nelson et al., 2002; Lu et al., 2008; Li et al., 2009; Moore et 
al., 2012; Han et al., 2014), positioning this region as a potential common mediator of 
anesthetic hypnosis. Furthermore, c-Fos expression in VLPO is positively correlated with 
isoflurane dose, suggesting that isoflurane may dose-dependently activate VLPO 
neurons (Moore et al., 2012). Activation of VLPO under anesthesia may arise from either 
disinhibition or from direct excitation. This has not been examined for many anesthetics, 
though isoflurane was shown to directly depolarize putative sleep-active VLPO neurons 
(Moore et al., 2012). However, not every VLPO neurons is activated by isoflurane. 
Single cell recordings within VLPO reveal two distinct subpopulations: isoflurane-
activated VLPO neurons, and isoflurane-inhibited VLPO neurons (Moore et al., 2012; 
McCarren et al., 2014). The isoflurane-activated neurons are also inhibited by 
norepinephrine, suggesting they are the sleep-active VLPO population (Moore et al., 
2012).  
On a functional level, VLPO lesions increase resistance to propofol, significantly 
increasing the time to LORR after administration and decreasing LORR duration (Zhang 
et al., 2015a). Lesions of VLPO neurons also increased wakefulness and decreased 
isoflurane sensitivity, though only acutely (Eikermann et al., 2011; Moore et al., 2012). 
The enhanced sensitivity to isoflurane observed at later timepoints is thought to be the 
result of sleep deprivation caused by the VLPO lesions, which increases sensitivity to 
anesthetics as discussed earlier (Tung et al., 2002). Conversely, inhibition of VLPO 
neurons, via activation of α2 adrenergic receptors, increases behavioral arousal under 
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isoflurane anesthesia (McCarren et al., 2014). Together, these results support a role of 
VLPO in regulating arousal under anesthesia. However, to what degree this is true 
remains an open question, as will be discussed later in this chapter. 
MnPO: Evidence for a role of the MnPO in anesthetic hypnosis is even less clear than 
VLPO. Exposure to isoflurane induces c-Fos in MnPO neurons, however, exposure to 
halothane, pentobarbital, and chloral hydrate do not (Lu et al., 2008; Han et al., 2014). 
This activation by isoflurane likely results from either disinhibition or secondary activation 
via VLPO or another anesthetic-activated region, as isoflurane-induced activation of 
MnPO does not occur in the presence of tetrodotoxin (Han et al., 2014). Additionally, 
reactivation of MnPO neurons that were active during dexmedetomidine-induced 
sedation does not promote sleep (Zhang et al., 2015b), suggesting that anesthetic-
activated MnPO neurons are not the same neurons that promote sleep.  
LPO: While the role of the LPO has not been investigated with general anesthetics, a 
recent study did examine the relationship between sleep and dexmedetomidine-induced 
sedation in the LPO. They show that the same neurons that are active during 
dexmedetomidine-induced sedation promote NREM sleep when re-activated at a later 
time, providing causal support for the shared circuitry hypothesis in the LPO. 
Additionally, re-activation of these dexmedetomidine-active LPO neurons produces a 
drop in body temperature, linking the POA to thermoregulation in both natural and drug-
induced forms of unconsciousness. Finally, deletion of Vgat from LPO neurons 
increases resistance to dexmedetomidine-induced sedation (Zhang et al., 2015b), 
suggesting that GABAergic LPO neurons specifically are required for dexmedetomidine-
induced sedation.  
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Challenges In Studying Arousal Regulation By The POA: 
Perhaps the largest challenge facing the study of arousal regulation by the POA is the 
immense heterogeneity of the region. In addition to regulating arousal state, the POA is 
involved in many essential social and homeostatic functions, including thermoregulation, 
thirst, parenting, and social behaviors (Sternson, 2013; Wu et al., 2014; Scott et al., 
2015; Tan et al., 2016; Allen et al., 2017; Leib et al., 2017).  
Heterogeneity exists even among arousal state regulating neurons in the POA, with 
sleep-active neurons interspersed among wake-active and arousal state-indifferent 
neurons. Recordings in the LPO and MPO found 21% of recorded neurons to be 
wake/REM-active, 66% to be sleep-active, and 13% to be state-indifferent (Takahashi et 
al., 2009). Additional recordings of 128 LPO neurons show that roughly 38% are 
wake/REM-active, 43% are sleep-active, and 19% are state-indifferent (Alam et al., 
2014). Similarly, although the VLPO and MnPO are more densely populated by sleep-
active neurons, roughly 20% of neurons in each area are estimated to be wake-active 
(Gaus et al., 2002; Alam et al., 2014). Because of this heterogeneity, a number of 
considerations must be taken into account when investigating arousal state regulation by 
the POA. 
One consideration is the method of activation used. This was highlighted in recent work 
demonstrating optogenetic activation of GABAergic POA neurons promotes wakefulness 
when stimulated at 10Hz (Chung et al., 2017), yet chemogenetic activation or 
optogenetic activation at lower frequencies (0.5Hz-4Hz) promotes NREM sleep (Kroeger 
et al., 2018; Vanini et al., 2020). This discrepancy is likely due to a conduction block 




Another consideration is the molecular marker used to distinguish the sleep-active and 
wake-active populations within the POA. The majority of studies investigating arousal 
state regulation by the POA have focused on two broad classes of neurons: the 
inhibitory GABAergic/galaninergic neurons typically shown to be sleep-active, and the 
excitatory glutamatergic neurons, typically associated with wake. However, the POA is 
also highly diverse at this molecular level. Single-cell RNA-sequencing of GABAergic 
and glutamatergic neurons within the POA has revealed an enormous level of molecular 
diversity within these two groups alone, consisting of nearly 70 subpopulations clustered 
based on gene expression (Moffitt et al., 2018). 
As a result, the assumption that inhibitory neurons are sleep-active and excitatory 
neurons are wake-active is not as straightforward as is often assumed. Though the 
majority of galaninergic VLPO neurons are sleep-active, roughly 20% of the population is 
actually wake-active (Gaus et al., 2002). Furthermore, of the POA neurons activated 
during recovery sleep, roughly 15% are glutamatergic (Zhang et al., 2015b). These 
functional differences within the broad class of excitatory POA neurons is further 
illustrated by work showing that activation of glutamatergic VLPO neurons promotes 
wake (Vanini et al., 2020), while activation of largely glutamatergic NOS1-expressing 
MnPO neurons causes entry into NREM sleep (Harding et al., 2018). This suggests that 
a secondary molecular marker, such as NOS1, may be a more accurate method of 
distinguishing between sleep- and wake-promoting neurons.  
Recent studies have shown that the molecular marker chosen to access the inhibitory 
population is also an important consideration. The GABA transporter, VGAT, is rarely 
expressed alongside Vglut2, the glutamatergic transporter. However, GABA synthesis 
genes Gad1 and Gad2 are sometimes expressed in the same neurons as Vglut2, 
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representing a population of POA neurons capable of coreleasing GABA and glutamate 
(Romanov et al., 2016; Moffitt et al., 2018). Thus, studies using Gad as a marker of 
inhibitory neurons in the POA may have unintentionally also been modulating 
glutamatergic signaling to an unknown degree. Together, this emphasizes that more 
specific markers are needed for more accurate investigations into POA arousal state 
regulation. 
The inability to accurately distinguish between sleep- and wake-active neurons within the 
POA has plagued investigations into the shared circuitry hypothesis of anesthesia as a 
result. Many of the anesthetic studies discussed above use GABA or galanin as a 
marker for the sleep-active neuronal population, yet do not also show that these same 
anesthetic-activated neurons are also involved in arousal regulation. Thus, though 
multiple lines of evidence demonstrate that general anesthetics and sedatives modulate 
the activity of the POA, and even the GABAergic/galaninergic POA, it is still unclear 
whether the same population of neurons involved in sleep/wake regulation also 
modulate arousal in response to general anesthetics, or whether these are two separate 
populations that exist in the same region.  
One piece of causal support for the shared circuitry hypothesis comes from a TetTag 
study investigating sleep and dexmedetomidine-induced sedation. Neurons tagged with 
excitatory DREADDs during dexmedetomidine sedation and later reactivated promote 
sleep, showing that an identical population of neurons is involved in both states (Zhang 
et al., 2015b). However, dexmedetomidine is a sedative known to induce 
unconsciousness that resembles NREM sleep, yet it does not induce a surgical plane of 
anesthesia. Therefore, the degree to which this result can be generalized to general 
anesthetics is not clear given the distinct types of unconscious induced by each. 
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Supporting this distinction between sedation and hypnosis is work showing that 
chemogenetic activation of VLPO and MnPO neurons affects arousal state, yet does not 
alter induction time or duration of LORR under isoflurane (Vanini et al., 2020).  
Therefore, it is clear that more causal investigations into the shared circuitry hypothesis 
are warranted. However, more specific molecular markers are needed in order to 
distinguish between the sleep- and wake-promoting subpopulations and understand how 
the POA regulates arousal under both natural and anesthetic-induced conditions. 
 
Role of Tachykinins in Arousal Regulation 
The ability of neuropeptides to exert longer-lasting and wider spreading effects 
compared to fast neurotransmitters such as GABA or glutamate makes them ideal 
candidates for regulating global brain states. This is supported by work in the SON 
showing that neurons expressing the peptides arginine vasopressin (AVP) and 
prodynorphin (Pdyn) modulate arousal under both sleep and general anesthesia (Jiang-
Xie et al., 2019). Recently, a set of molecular markers was uncovered that labels POA 
neurons capable of modulating the arousal state (Chung et al., 2017). One of these 
markers is the tachykinin-1 gene (Tac1), a member of the tachykinin neuropeptide 
family. 
The Tac1 gene, also known as preprotachykinin-A, encodes 4 tachykinin variants in 
mammals: neurokinin α, neuropeptide K, neuropeptide γ, and substance P (Steinhoff et 
al., 2014). These tachykinins are highly expressed in the brain and the enteric nervous 
system (von Euler and Gaddum, 1931), where they stimulate gut motility and fluid 
secretion from the intestinal epithelium. In addition to their effect on the digestive tract, 
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tachykinins are also involved in a wide variety of biological process and diseases, 
including pain, inflammation, stress, anxiety, depression, reproduction, and cancer 
(Steinhoff et al., 2014). They exert their actions via three G-protein coupled receptors 
(GPCRs) that are widely expressed across the brain: NK1R, NK2R, and NK3R (Steinhoff 
et al., 2014). Within the brain, Tac1 neurons are most concentrated in the hypothalamus, 
striatum, and amygdala, though there are also Tac1-expressing neurons scattered more 
sparsely throughout the rest of the brain (Lein et al., 2007).  
In addition to the Chung et al. study, tachykinin neuropeptides have been previously 
linked to sleep and wake regulation. Substance P is expressed by arousal state-
regulating neurons, such as the serotonergic RN neurons and dopaminergic VTA 
neurons (Otsuka and Yoshioka, 1993; Sergeyev et al., 1999). Nighttime intravenous 
infusions of substance P in healthy adults increases time spent awake as well as REM 
latency compared to saline infusions (Lieb et al., 2002). Additionally, ICV administration 
of substance P also increases both time spent awake and latency of sleep onset in mice 
(Andersen et al., 2006). One proposed mechanism for this enhanced wakefulness is 
substance P-mediated activation of wake-promoting LC neurons, known to express 
tachykinin receptors (Otsuka and Yoshioka, 1993). Indeed, local administration of 
substance P depolarizes LC neurons and increases firing rate (Guyenet and Aghajanian, 
1977). However, it must be noted that when infused directly into the VLPO of mice, 
substance P promotes sleep (Zhang et al., 2004). Additionally, sleep-active nNOS 
neurons in the cortex express tachykinin receptors and are depolarized by substance P 
(Dittrich et al., 2012), suggesting that substance P has region specific effects on sleep 
and wake. Given these roles in modulating sleep and wake, tachykinin-1 is a promising 
molecular marker for arousal state-regulating neurons. 
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Goals of Thesis 
Thus, the aim of this thesis was to use Tac1 as a more specific molecular marker of 
arousal state-regulating neurons in the POA to examine their ability to modulate arousal 
state under both natural sleep and in response to anesthesia. In Chapter 1, I show that 
chemogenetic activation of POA Tac1 neurons strongly promotes wakefulness and 
locomotion over natural sleep, confirming a role in arousal state regulation. In Chapter 2, 
I then show that these same neurons also promote wakefulness over isoflurane and 
sevoflurane anesthesia, restoring consciousness during ongoing doses of both 























Figure 1.1: Current understanding of wake-promoting circuitry in the mouse brain. 
During periods of wake, the wake-promoting nuclei (green circles) become active and 
inhibit sleep-promoting regions (dark green lines), particularly the POA. Inhibitory 
projections to other sleep-promoting regions have yet to be established. The orexinergic 
LH stabilizes the wake state by exciting many of the wake-promoting areas (light green 
arrows). Many of the wake-promoting regions (LH, TMN, SuM, RN, vPAG, LC) also 
promote wakefulness by activating the cortex, as illustrated by the BF (light green 












Figure 1.2: Current understanding of NREM sleep circuitry in the mouse brain. At 
the onset of NREM sleep, sleep-promoting neurons (red circles) become active and 
inhibit many of the wake-promoting nuclei of the brain (green circles) to reinforce and 
stabilize the sleep state. Figure created with BioRender.com. 
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CHAPTER 2 – Activation of POA Tac1 Neurons Increases Wakefulness 
Over Natural Sleep 
Introduction 
Behavioral states of arousal are controlled by a network of nuclei spread throughout the 
brain. One of the earliest studied regions was the hypothalamus, whose role in sleep 
and wake regulation was first uncovered by Constantin von Economo during a viral 
pandemic in the early 20th century (von Economo, 1930). Since then, the hypothalamus 
is increasingly recognized as a loose confederation of autonomous neurons that regulate 
many essential social and homeostatic functions (Sternson, 2013; Wu et al., 2014; Scott 
et al., 2015; Tan et al., 2016; Allen et al., 2017; Leib et al., 2017), including sleep and 
wake (Szymusiak et al., 2007). Specifically, the preoptic area of the hypothalamus 
(POA) is known to modulate natural forms of arousal (sleep and wake) (Gallopin et al., 
2000; Lu et al., 2000, 2002; McGinty and Szymusiak, 2001; Gong et al., 2004; Chung et 
al., 2017).   
A major obstacle to understanding arousal state regulation by the POA is the inherent 
heterogeneity of the region, with sleep-active neurons existing alongside wake-active 
and arousal state-indifferent neurons (Kaitin, 1984; Szymusiak and McGinty, 1986; 
Szymusiak et al., 1998; Takahashi et al., 2009). Previous work examining arousal state 
regulation has largely focused on the role of two broad classes of neurons: the inhibitory 
GABAergic/galaninergic and excitatory glutamatergic neurons. However, single-cell 
RNA-sequencing of GABAergic and glutamatergic neurons within the POA has revealed 
an enormous level of molecular diversity within these two groups, consisting of nearly 70 
subpopulations clustered based on gene expression (Moffitt et al., 2018). Perhaps 
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because of this heterogeneity, investigations of arousal regulation, particularly 
anesthetic-induced unconsciousness, focusing on GABAergic and glutamatergic 
neuronal subtypes are not as straightforward as originally thought, as discussed in 
Chapter 1. Thus, a more refined targeting of POA cell types is needed. 
Work implicating tachykinins in sleep and wake (Lieb et al., 2002; Zhang et al., 2004; 
Andersen et al., 2006; Chung et al., 2017) led us to hypothesize that Tac1 POA neurons 
are involved in arousal state regulation, and that modulating their activity would thus 
modulate the arousal state of the animal.  
 
Results 
Chemogenetic activation of POA Tac1 neurons increases wakefulness as 
measured both by ambulatory actigraphy and EEG/EMG 
To reversibly activate Tac1 neurons in the POA, we bilaterally expressed Cre-dependent 
excitatory hM3DG(q)-mCherry designer receptors (hereafter referred to as hM3Dq) in 
the POA of Tac1-Cre mice (Figure 2.1, Figure 2.2A and 2.2B). Fluorescent in situ 
hybridization demonstrates that all of the transfected neurons expressing mCherry 
mRNA also express endogenous tac1 mRNA (893 cells from n=3 mice, Figure 2.2C), 
thus confirming that DREADD expression was limited to the intended targeted 
population. Relative to vehicle, intraperitoneal (i.p.) administration of 3mg/kg clozapine-
N-oxide (CNO) significantly increased expression of c-Fos, a marker of antecedent 
neuronal activity, in POA hM3Dq-positive neurons (p=0.0059, Figure 2.2D and 2.2E), 
confirming that the targeted neuronal population was successfully activated. In a 
separate cohort of Tac1-Cre mice, Cre-dependent inhibitory hM4DG(i)-mCherry 
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designer receptors (hereafter referred to as hM4Di) were bilaterally expressed to 
examine the effects of reversible inhibition. Examination of c-Fos expression confirmed 
that i.p. CNO significantly decreased c-Fos in POA hM4Di-positive neurons (p=0.0311, 
Figure 2.2F and 2.2G), verifying that the targeted neurons were inhibited compared to 
vehicle.  
To determine how modulating POA Tac1 neuronal activity alters rest and activity 
patterns, locomotion was assessed using an infrared beam break system. Compared to 
vehicle, activation of POA Tac1 neurons with 3mg/kg CNO at ZT0 (n=6 mice) more than 
doubled the number of infrared beams broken over the 4 hour recording (p<0.0001; 
7,416.3 ± 1,493.6 after vehicle compared to 17,091.0 ± 2,433.8 after CNO, Figure 
2.2H). POA Tac1 inhibition (n=7 mice) did not alter the number of beams broken 
(p>0.9999; 8,740.3 ± 979.9 after vehicle compared to 7,963.9 ± 1,612.5 after CNO, 
Figure 2.2H). To rule out potential confounding effects of viral injection and non-specific 
CNO actions, beam break actigraphy was recorded in a separate group of Tac1-Cre 
mice expressing only mCherry in the POA (n=5 mice) run concurrently with the hM3Dq 
group. Relative to vehicle, administration of CNO did not alter the number of beams 
broken (p=0.8152; Figure 2.2H).  
Given these unexpected results, the effects of POA Tac1 neuronal activation on sleep 
and arousal was measured using the polysomnographic gold standard for sleep scoring 
based upon electroencephalography (EEG) and electromyography (EMG). Not only can 
these two measures distinguish quiet wakefulness from sleep, they also allow for an 
examination of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep 
(Figure 2.3A). Tac1-Cre mice expressing either hM3Dq (n=5 mice), hM4Di (n=8 mice), 
or mCherry (n=5 mice) in the POA were implanted with EEG/EMG leads. EEG and EMG 
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waveforms were recorded for 1 hour prior to and 4 hours following administration of 
3mg/kg CNO or vehicle. No differences were observed between groups in the hour 
preceding treatment (Figure 2.5 & 2.6). Over the 4 hours following injection, however, 
CNO significantly increased wakefulness compared to vehicle in hM3Dq mice, as 
illustrated in the example spectrograms (Figure 2.3B & 2.3D) and corresponding 
hypnograms (Figure 2.3C & 2.3E). In aggregate, hM3Dq mice showed a 60% increase 
in wakefulness (p<0.0001; 60.8% ± 7.5% after vehicle compared to 97.2% ± 1.7% after 
CNO, Figure 2.3F) and a 93% decrease in NREM sleep following CNO administration 
(p<0.0001; 38.8% ± 7.4% after vehicle compared to 2.8% ± 1.7% after CNO, Figure 
2.3G). Likely due to the sparsity of REM sleep at the beginning of the rest phase, 
significant differences in REM sleep times were not observed (p=0.1366). Most notably, 
CNO also drastically increased the latency to the first episode of NREM sleep following 
injection (p<0.0001; 342.1 ± 152.7s after vehicle compared to 4,084.6 ± 792.8s after 
CNO, Figure 2.3I). While chemogenetic activation of POA Tac1 neurons nearly 
abolished sleep in hM3Dq mice, inhibition of this population did not alter time spent in 
each state or latency to first NREM period (Figure 2.3F-2.3I). CNO did not affect any of 
the parameters measured in control mCherry mice (Figure 2.3F-2.3I), eliminating the 
possibility of non-specific drug effects. Collectively, these results show that 
chemogenetic activation of POA Tac1 neurons strongly promotes wakefulness, while 
inhibition does not significantly alter sleep or wakefulness.  
Chemogenetic activation of POA Tac1 neurons stabilizes and consolidates 
wakefulness 
In addition to increasing time spent awake at the expense of sleep, activation of POA 
Tac1 neurons substantially altered the architecture of both states. Administration of CNO 
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stabilized and consolidated the waking state, increasing the average wake bout duration 
78-fold (p<0.0001; 22.2 ± 6.1s after vehicle compared to 1,738.6 ± 837.1s after CNO, 
Figure 2.4A), while also dramatically decreasing the number of wake bouts (p<0.0001; 
528.4 ± 70.9 after vehicle compared to 34.6 ± 20.8 after CNO, Figure 2.4D). 
Accordingly, activation of Tac1 neurons destabilized NREM sleep, decreasing both the 
average bout duration (p=0.0006; 12.6 ± 0.9s after vehicle compared to 6.8 ±1.5s after 
CNO, Figure 2.4B) and number of bouts (p<0.0001; 529.6 ± 71.5 after vehicle 
compared to 33.8 ± 20.9 after CNO, Figure 2.4E). Neither the average bout duration nor 
the number of REM bouts was significantly affected by POA Tac1 activation (p=0.5054 
and p=0.1189, respectively, Figure 2.4C & 2.4F). POA Tac1 inhibition had no effect on 
sleep and wake architecture (Figure 2.4). CNO itself failed to alter sleep architecture in 
control mCherry mice relative to vehicle (Figure 2.4).  
Chemogenetic activation of POA Tac1 neurons increases movement but does not 
affect place preference in an open field 
Video recorded during EEG/EMG sessions, together with beam break actigraphy data, 
demonstrated that activating POA Tac1 neurons increased locomotor activity. To 
determine whether increased anxiety might account for the increased wakefulness and 
locomotion, we examined whether activation of POA Tac1 neurons altered ambulatory 
activity in an open field (Walsh and Cummins, 1976). Following i.p. administration of 
3mg/kg CNO or vehicle, Tac1-Cre mice expressing hM3Dq receptors (n=16 mice), 
hM4Di receptors (n=7 mice), or mCherry only (n=15 mice) in the POA were placed in a 
circular open field and allowed to explore for 20 minutes. Each animal’s position within 
the field was tracked by a video camera mounted overhead and analyzed offline. 
Activation of POA Tac1 neurons increased the total distance traveled over the session 
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by 43% compared to vehicle (p<0.0001; 166.6 ± 9.4m after vehicle compared to 238.4 ± 
18.0m after CNO, Figure 2.7A) and also increased average ambulatory speed 
(p<0.0001; 0.097 ± 0.004m/s after vehicle compared to 0.137 ± 0.007m/s after CNO, 
Figure 2.7B). These effects were specific to POA Tac1 activation, as CNO did not alter 
total distance traveled or average speed in the inhibitory hM4Di or control mCherry mice 
relative to vehicle (Figure 2.7A and 2.7B). 
In addition to measures of speed and ambulatory activity, the open field paradigm is also 
used to assess anxiety phenotypes in many species (Walsh and Cummins, 1976), with 
increased time spent in the outer zone of the open field indicative of heightened anxiety 
(Treit and Fundytus, 1988; Simon et al., 1994). To assess potential effects of POA Tac1 
activation on anxiety, place preference within the open field was determined using the 
percent of time spent outside the center region of the field. To remove potential bias 
introduced by arbitrarily defining the center region, time spent outside the center was 
calculated as a function of the field’s radius (Figure 2.7C). There were no differences in 
place preference distributions between treatments regardless of the threshold used to 
define the center and the periphery of the open field for hM3Dq (p=0.9065, Figure 
2.7D), hM4Di (p=0.9968, Figure 2.7E) and mCherry (p=1.00, Figure 2.7E) mice. 
Together, these data show that activation of POA Tac1 neurons increases ambulatory 
activity, but this increase in activity does not appear to be a consequence of increased 
anxiety.  
POA Tac1 neurons project to numerous wake-promoting nuclei across the brain 
To investigate how POA Tac1 neurons might promote wakefulness, projections of 
hM3Dq-expressing POA Tac1 neurons were mapped histologically. We found dense 
hM3Dq-mCherry+ projections to numerous established wake-promoting nuclei across 
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the brain, including the orexinergic neurons of the lateral hypothalamus (LH) (Figure 
2.8A), histaminergic tuberomammillary nucleus (TMN) neurons (Figure 2.8B), 
dopaminergic ventral periaqueductal gray (vPAG) and ventral tegmental area (VTA) 
neurons (Figure 2.8C & 2.8D), and noradrenergic locus coeruleus (LC) neurons (Figure 




Here, we demonstrate that chemogenetic activation of POA Tac1 neurons strongly 
promotes and consolidates wakefulness while also enhancing locomotor activity. 
Chemogenetic inhibition of this population, while incomplete, did not affect arousal state, 
suggesting the POA Tac1 neurons are sufficient, but perhaps not necessary, for 
wakefulness. These wake-promoting results add to a growing body of evidence 
supporting a role for the POA in wake promotion, and emphasize that the POA is not an 
exclusively somnogenic region. 
Tachykinin neuropeptides have been previously linked to sleep and wake regulation. 
Nighttime intravenous infusions of substance P, a product of the Tac1 gene, in healthy 
adults increases time spent awake as well as REM latency compared to saline infusions 
(Lieb et al., 2002). Additionally, ICV administration of substance P also increases both 
time spent awake and latency of sleep onset in mice (Andersen et al., 2006). One 
proposed mechanism for this enhanced wakefulness is substance P-mediated activation 
of wake-promoting LC neurons, known to express tachykinin receptors (Otsuka and 
Yoshioka, 1993). Indeed, local administration of substance P depolarizes LC neurons 
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and increases firing rate (Guyenet and Aghajanian, 1977). POA Tac1 projections to the 
LC, as well as the LH, TMN, vPAG, and VTA (Figure 5) provide a likely endogenous 
source of substance P to enhance wakefulness. However, synaptic connections to these 
regions will need to be confirmed using channelrhodopsin-assisted circuit mapping 
(CRACM) (Petreanu et al., 2007) or a higher resolution microscopy method such as 
electron microscopy. It must also be noted that substance P signaling is not uniformly 
arousal-promoting. When infused directly into the VLPO of mice, substance P promotes 
sleep (Zhang et al., 2004), suggesting that substance P has region-specific effects on 
arousal.  
Chemogenetic activation of POA Tac1 neurons strongly stabilized the wake state, 
decreasing the number of transitions between sleep and wake while greatly increasing 
the average length of wake bouts. This is in contrast to previously published results 
describing NREM-promoting effects of POA Tac1 activation (Chung et al., 2017). Given 
single-cell molecular profiling of the POA showing that Tac1 is expressed in both 
excitatory and inhibitory POA neurons (Moffitt et al., 2018), it is likely that distinct 
populations of sleep-promoting and wake-promoting Tac1 neurons exist within the 
region. The chemogenetic activation strategy used in our study almost certainly recruited 
more POA neurons compared to the optogenetic strategy employed by Chung et al., 
allowing for the possibility that activation of the wake-promoting Tac1 neurons in our 
study overpowered any sleep-promoting Tac1 neurons in the region. A second possible 
explanation for these divergent results is a potential conduction block caused by 10Hz 
optogenetic stimulation. Galaninergic POA neurons stimulated at 10Hz promote wake 
(Chung et al., 2017). However, optogenetic stimulation at lower frequencies (0.5-4Hz) 
that more closely match the endogenous firing rate during NREM sleep increases NREM 
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sleep (Kroeger et al., 2018). Endogenous state dependent firing rates of POA Tac1 
neurons remain unknown. A third potential explanation relates to differences in neuronal 
transfection across the POA. While viral spread for animals used in this study are given 
(Figure 2.1), the extent of transfection was not shown by Chung et al.  
More difficult to reconcile are the divergent effects of chemogenetic inhibition, which had 
no effect on sleep in this study but was previously shown to promote wakefulness 
(Chung et al., 2017). Variable efficacy of chemogenetic inhibition may underlie these 
differences, as incomplete suppression of activity of hM4Di-expressing neurons occurs 
whether CNO is administered locally or systemically (Mahler et al., 2014; Chang et al., 
2015; Cichon and Gan, 2015). Our c-Fos immunohistochemistry reflects these findings, 
as the number of c-Fos-expressing hM4Di neurons was not completely abolished, but 
rather decreased by roughly 30% after CNO compared to vehicle. Once again, a 
difference in viral transfection between the two studies may also explain the divergent 
effects of chemogenetic inhibition.  
Not only did activation of POA Tac1 neurons stabilize wakefulness, it also increased 
ambulatory activity, as demonstrated by our beam break and open field results. This is 
not the first instance of a link between tachykinins and locomotion. Injections of 
substance P into the brainstem of lampreys, rodents, and cats induce bouts of locomotor 
activity, suggesting an evolutionarily conserved role for tachykinins in modulating 
locomotion (Garcia-Rill and Skinner, 1987; Kinjo et al., 1990; Barthe and Clarac, 1997; 
Brocard et al., 2005). Additionally, substance P and neurokinin A, another product of the 
Tac1 gene, produce a dopamine-mediated increase in locomotor activity in an open field 
when injected into the VTA of rats (Stinus et al., 1978; Kelley et al., 1979; Kalivas et al., 
1985). To our knowledge, the endogenous source of tachykinins in these regions has yet 
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to be identified. However, our histological identification of POA Tac1 projections to the 
VTA suggests tachykinin release from these neurons as a potential mechanism 
underlying the enhanced locomotor phenotype observed after POA Tac1 activation. 
Multiple neuronal populations within the VTA are also known to regulate sleep and 
wakefulness (Yu et al., 2019), making the VTA a potential mediator of both the 
locomotor and arousal promoting effects of POA Tac1 activation.  
Analysis of open field locomotion allowed for a simultaneous investigation into potential 
effects on anxiety. Sleep and wake disturbances are known to occur in a number of 
psychiatric conditions, including anxiety (Breslau et al., 1996; Monti and Monti, 2000; 
Ohayon and Roth, 2003; Khazaie and Masoudi, 2016). Furthermore, tachykinins have 
previously been implicated in anxiety and other emotional behaviors in rodents. Mice 
with a targeted deletion of either the Tac1 gene or neurokinin 1 receptor gene show 
reduced anxiety in a number of paradigms, including the open field (Rupniak et al., 2001; 
Santarelli et al., 2001; Bilkei-Gorzo et al., 2002). Similarly, administration of neurokinin 1 
receptor antagonists in rodents reduces anxiety-related behaviors (Teixeira et al., 1996; 
Heldt et al., 2009), while agonists induce an anxiogenic response (Teixeira et al., 1996). 
Given these links, we questioned whether the increased wakefulness observed after 
POA Tac1 activation was due to anxiety. Mice typically spend more time exploring the 
periphery of an open field compared to the open center area, with an increase in time 
spent in the center indicative of anxiolysis (Walsh and Cummins, 1976; Simon et al., 
1994). An unbiased comparison of place preference probability distributions within the 
open field between CNO and vehicle treated mice expressing hM3Dq, hM4Di, or 
mCherry alone revealed that POA Tac1 neurons have no effect on place preference and 




Materials and Methods 
Mice 
Studies were approved by the Institutional Animal Care and Use Committee at the 
University of Pennsylvania and were conducted in accordance with National Institutes of 
Health guidelines. Chemogenetic experiments were performed in male and female Tac1-
IRES-Cre mice (Jackson Laboratories, stock 021877; 43 females and 40 males) aged 
10-18 weeks, weighing 18-25g at the time of surgery. Male and female mice were 
distributed equally across groups in each experiment. Littermates were split between 
experimental and control groups while also ensuring equal distribution of males and 
females between groups. All mice were housed on a reverse 12h:12h light/dark cycle 
(ZT0/lights on 7:00pm) with ad libitum access to food and water.  
Viral Vectors and Chemicals 
Cre-dependent adeno-associated viral vectors (AAV8-hSyn-DIO-hM3Dq-mCherry, 
Addgene, 44361; AAV8-hSyn-DIO-hM4Di-mCherry, Addgene, 44362) were used to 
selectively express excitatory hM3Dq or inhibitory hM4Di receptors in Tac1 hypothalamic 
neurons. Control animals received a Cre-dependent adeno-associated viral vector 
containing mCherry only (AAV8-hSyn-DIO-mCherry, Addgene, 50459). Clozapine-N-
oxide (CNO, Sigma-Aldrich) was prepared fresh for each experiment by dissolving in 
sterile saline to a concentration of 0.3mg/ml. CNO dosing for all experiments was 
3mg/kg. 
Surgical Procedures 
Mice were anesthetized with 2.5% isoflurane in 100% oxygen for induction, and 
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maintained on 1.5% isoflurane for the remainder of the surgery. After lack of response to 
a toe pinch, mice were placed on a stereotaxic frame (Kopf Model 902). Eyes were 
protected by an eye ointment and core temperature was maintained at 37±0.5°C using a 
closed-loop heating pad (CWE Inc). To target the POA, mice received bilateral 300nl 
microinjections of virus delivered using a 33G, 10ul Hamilton syringe (Hamilton 
Company, 80008) mounted on a stereotaxic microinjection syringe pump (Stoelting Co). 
The injection coordinates relative to bregma were: AP -0.10mm; ML ±0.70mm; DV -
5.70mm. Following injection, the syringe was held in position for 10 minutes to avoid 
virus reflux up the syringe tract (Cardin et al., 2010). Following bilateral injections, the 
incision was sutured closed, isoflurane was discontinued, and animals received 0.5mg 
cefazolin and 0.125mg meloxicam to maintain analgesia. For sleep recordings, 
EEG/EMG leads were constructed and implanted following viral injections as previously 
described (Wasilczuk et al., 2016). 6 epidural EEG leads were implanted 0.65mm lateral 
to midline on both hemispheres, ranging from 2.45mm anterior to bregma to 2.75mm 
posterior to bregma. Additionally, 2 EMG leads were implanted in the dorsal neck 
muscles. The headpiece was secured to the skull using dental cement (A-M Systems). 
All mice were allowed to recover for a minimum of two weeks prior to the start of 
habituation.  
Fluorescent In Situ Hybridization 
In situ hybridization was performed with the RNAscope Fluorescent Multiplex Kit 
(Advanced Cell Diagnostics Inc) following the pretreatment protocol for fixed frozen 
sections. Mice were transcardially perfused with PBS followed by 4% paraformaldehyde, 
brains were then removed and post-fixed overnight in 4% paraformaldehyde. Brains 
were then placed in 15% sucrose until tissue sank, and repeated in 30% sucrose. Brains 
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were embedded in Tissue-Tek O.C.T Compound and the POA was sectioned at 14µm 
by cryostat and mounted onto Superfrost Plus slides. FISH protocol was then run 
according to manufacturer’s instructions, with the Target Retrieval pretreatment step 
extended to 8 minutes and tac1 C2 and mCherry C3 probes.  
Immunohistochemistry for c-Fos 
Mice expressing hM3Dq or hM4Di receptors in the POA received an intraperitoneal (i.p.) 
injection of vehicle or CNO 2 hours prior to sacrifice. Mice were then deeply 
anesthetized with isoflurane and transcardially perfused with ice cold PBS followed by 
4% paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde 
overnight. Brain tissue was then sectioned via compresstome (Precisionary Instruments) 
at 40µm and standard c-Fos immunohistochemistry was performed on sections 
containing the hypothalamus. Sections were permeabilized and blocked in 2.5% normal 
goat serum in PBST (2% TritonX-100 in PBS) for 1 hour at room temperature, followed 
by an overnight incubation at 4° C in rabbit anti-cFos primary antibody (Cell Signaling 
Technologies, 1:1000). Sections were then washed in PBS, followed by a 2 hour 
incubation with Alexa Fluor 488 goat anti-rabbit secondary antibody (ThermoFisher, 
1:200). Following a final wash in PBS, sections were mounted and cover slipped with 
mounting medium containing a DAPI counterstain (Vector Laboratories).  
Immunohistochemistry for Projection Targets 
Mice were transcardially perfused and brains postfixed and sectioned as described 
above. To visualize fiber projections in a variety of brain regions, sections were 
permeabilized and blocked in 2.5% normal goat serum in PBST (2% TritonX-100 in 
PBS) for 1 hour at room temperature, followed by an overnight incubation at 4° C in 
primary antiserum against mCherry (rabbit anti-RFP, Rockland Inc, 1:1000 or chicken 
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anti-mCherry, Abcam, 1:1000) and the molecular marker of interest for each region 
(chicken anti-tyrosine hydroxylase, Abcam, 1:1000; rabbit anti-histidine decarboxylase, 
American Research Products Inc, 1:1000; or mouse anti-orexin A, R&D Systems, 
1:1000). Sections were washed in PBS followed by a 2 hour incubation with the 
appropriate secondary antibodies (Alexa Fluor 594 goat anti-rabbit, ThermoFisher, 
1:200; Alexa Fluor 594 goat anti-chicken, ThermoFisher, 1:200; Alexa Fluor 647 goat 
anti-rabbit, ThermoFisher, 1:200; Alexa Fluor 647 goat anti-mouse, ThermoFisher, 
1:200; Alexa Fluor 647 goat anti-chicken, ThermoFisher, 1:200). Following a final wash 
in PBS, sections were mounted and coverslipped with mounting medium containing a 
DAPI counterstain (Vector Laboratories).  
Imaging and Cell Counting 
Sections used for cell counting were imaged at 20x using a confocal microscope (SP5II, 
Leica Microsystems). Counting was performed using ImageJ (Schindelin et al., 2012) 
and conducted by a blinded experimenter. Only mice that displayed mCherry expression 
in the POA were included in analysis. The fraction of mCherry-positive neurons also 
positive for c-Fos were quantified for each 40um section, and subsequently averaged for 
each animal. FISH sections and sections stained for projection targets were imaged at 
40x and 63x also using a confocal microscope. The number of mCherry-positive neurons 
also positive for Tac1 was quantified for each image. Imaging for injection localization 
was performed using epifluorescence microscopy (Olympus BX41).  
Viral Transfection Mapping 
To construct viral transfection heat maps, coronal sections containing viral mCherry 
expression were imaged at 10x on an epifluorescence microscope. Each image was 
then matched to the corresponding section on the mouse brain atlas, and an outline 
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containing the transfected region was traced on an outline of the corresponding atlas 
image overlaid on the microscopy image. This was repeated for all mice in the group and 
the outlines for each atlas section were then aggregated in Matlab. Transfected regions 
of interest were binarized and summed together for each coronal section across all 
animals. A 2-D Gaussian kernel with standard deviation of 3 was applied as a smoothing 
filter for creation of the final heat map.  
Assessment of Home Cage Ambulatory Activity 
Mouse ambulation was recorded using a 1-dimensional home cage locomotor infrared 
beam system and accompanying Accuscan Fusion 4.1 software (Omnitech Electronics 
Inc). Actigraphy was recorded for 4 hours following i.p. injection of vehicle or CNO at the 
beginning of the light cycle (ZT0-ZT4). Injection order was randomized and recordings 
were separated by at least 48 hours. Total number of beams broken during the 4 hour 
period was then compared between conditions.  
Assessment of Sleep and Wake 
At least 2 weeks after viral injection and EEG/EMG implantation, mice were habituated 
to tethering in the recording area for 3 days. All recordings were performed in home 
cages. On experimental days, mice underwent 1 hour of baseline EEG/EMG recording in 
the last hour of the dark cycle. An hour later (ZT0, onset of light cycle) mice received an 
i.p. injection of vehicle or CNO and EEG/EMG was continuously recorded for 4 hours 
post-injection. For hM4Di experiments, recordings took place at the opposite circadian 
time (baseline during last hour of the light cycle, injections at ZT12) to maximize any 
potential sleep-promoting effects. Injection order was randomized and recordings were 
separated by at least 48 hours for all groups. Signals were recorded and digitized at 
1000 Hz using 32 channel headstages (Intan Technologies, Los Angeles, CA) and open 
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source software (Siegle et al., 2017). EEG signals were filtered between 1 and 100 Hz 
using a 5th order zero-phase Butterworth filter and mean re-referenced. EMG signals 
were filtered above 100 Hz using the same filter. Spectral power estimation was 
computed using previously published code (Hudson et al., 2014). EEG/EMG was then 
used to classify brain states as NREM sleep, REM sleep, or wakefulness using a 5 
second sliding window with a 2.5 second overlap (Weber et al., 2015). Delta power was 
summed from 1-5 Hz while theta power was summed from 6-12 Hz. Epochs of NREM 
sleep were identified by high delta power (greater than mean power over entire 
recording) with low muscle tone (lower than mean power over entire recording). REM 
sleep was characterized by low delta power (less than mean power over entire 
recording), high theta power (greater than mean plus standard deviation over entire 
recording) with muscle atonia (EMG lower than mean power over entire recording). All 
other windows were classified as wake. Therefore, the wake state consisted of windows 
of high EMG power and high delta with EMG tone. Classification was performed in 
Matlab and manual verification confirmed findings. Total time, number of bouts, and 
average bout duration were calculated for each state and compared between groups. 
Finally, latency to the first NREM period was also compared between treatment 
conditions in all groups.  
Open Field Video Tracking 
Prior to the start of their open field recording, mice received i.p injections of vehicle or 
CNO. 30 minutes later, the mouse was placed in a circular open field (radius 76cm) and 
ambulatory activity was recorded for 20 minutes with a camera mounted above the open 
field. Movement was tracked offline using custom Matlab software previously described 
(Wasilczuk et al., 2018). Total distance traveled and average speed were quantified over 
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the entire recording. To address potential changes in place preference within the field, 
the probability of the mouse being outside the center region of the field was calculated 
for center regions of various radii and compared between treatments for each group. 
Injection order was randomized and trials were separated by at least 48 hours.  
Quantification and Statistical Analysis 
Data were analyzed using Matlab 2019b (Mathworks, MA) using the Statistics and 
Machine Learning Toolbox and Prism v8.0 (GraphPad Software Inc). All data collection 
was randomized and counter-balanced. All data were tested for normality and are 
reported as mean ± standard error of the mean. A p value <0.05 was considered 
statistically significant for all comparisons. Behavioral changes as a function of virus 
(hM3Dq-mCherry, hM4Di-mCherry, or mCherry) and treatment (vehicle or CNO) were 
evaluated using a two-way repeated-measures ANOVA followed by Bonferroni’s 
correction for multiple comparisons. The percentage of active cells (c-Fos+) after 
administration of vehicle or CNO was compared using a two-tailed unpaired t test. The 
Kolmogorov–Smirnov test was used to determine any differences in place preference 
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Figure 2.1: Localization of hM3Dq- and hM4Di-transduced neurons (visualized as 
mCherry-positive somas) for individual Tac1-IRES-Cre mice. Heatmap showing 
overlapping regions of transfected neurons from hM3Dq-expressing mice (left column) 
and hM4Di-expressing mice (right column). Abbreviations: aca, anterior commissure; 
MPO, medial preoptic area; LPO, lateral preoptic area; MPN, medial preoptic nucleus; 
VLPO, ventrolateral preoptic area; f, fornix; oc, optic chiasm; AHA, anterior hypothalamic 
















Figure 2.2: Chemogenetic Activation of POA Tac1 Neurons Increases Ambulatory 
Activity. (A) Schematic representation of AAV injection into the POA of Tac1-IRES-Cre 
mice for expression of the excitatory DREADD receptor hM3Dq-mCherry, inhibitory 
DREADD receptor hM4Di-mCherry, or control mCherry fluorophore. (B) Representative 
































































































and (F) are taken from region outlined by solid white box. (C) Fluorescent in situ 
hybridization for mCherry (red) and tac1 (green) confirmed viral expression limited to the 
targeted neuronal population. (D) Proportion of hM3Dq-expressing neurons (red) that 
also express c-Fos (green) is increased after administration of 3mg/kg CNO, quantified 
in (E). (F) 3mg/kg CNO decreased c-Fos expression in hM4Di-expressing neurons 
compared to vehicle, quantified in (G). White arrows in (D) and (F) indicate double 
positive neurons. Asterisk indicates a significant difference (*p<0.05, **p<0.01) using a 
two-tailed unpaired t test. (H) CNO significantly increased ambulatory activity in hM3Dq-
expressing animals as measured by the number of beams broken in an infrared beam 
actigraphy system. Asterisk indicates a significant difference (****p<0.0001) using a two-
way repeated-measures ANOVA with Bonferroni’s correction for multiple comparisons. 
Scale bar represents 200um in (B) and 50um in (C), (D), and (F). Data are shown as 












Figure 2.3: Chemogenetic Activation of POA Tac1 Neurons Increases Time Spent 
Awake as Measured by EEG/EMG. (A) Representative EEG and EMG traces during 
wakefulness, non-rapid eye movement (NREM) sleep, and rapid eye movement (REM) 
sleep. EKG signal at approximately 10Hz corresponds to a mouse heart rate of roughly 
600 bpm and is also distinguishable in the EMG traces. (B and D) Representative 
spectrograms displaying changes in EEG power density from the same hM3Dq-
expressing mouse during the hour prior to, and 4 hours following injection of vehicle (B) 
or 3mg/kg CNO (D). The white dashed line indicates timing of intraperitoneal injection. 
(C and E) Hypnograms showing sleep and wake state assignments corresponding to 
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occurring over a 5 minute period in the vehicle-treated, but not CNO-treated mouse. (F-
H) Quantification of time spent in wakefulness (F), NREM sleep (G), and REM sleep (H) 
during the 4 hours following injection of vehicle or CNO. Administration of CNO 
increased time spent awake at the expense of NREM sleep in hM3Dq-expressing mice 
but not in hM4Di-expressing mice or controls. (I) Latency to the first NREM period was 
also increased following injection of CNO in hM3Dq-expressing mice only. Asterisks 
indicate a significant difference (****p<0.0001) from vehicle using a two-way repeated 
measures ANOVA with Bonferroni’s correction for multiple comparisons. Data in (F-I) are 















Figure 2.4: Chemogenetic Activation of POA Tac1 Neurons Stabilizes and 
Consolidates Wakefulness. (A) Administration of 3mg/kg CNO stabilized and 
consolidated periods of wake in hM3Dq-expressing mice, markedly increasing the 
average wake bout duration (A) (note the logarithmic scale) while decreasing NREM 
bout duration (B). REM bout duration was not affected (C). CNO decreased the average 
number of wake bouts (D) as well as NREM bouts (E). Again, average number of REM 
bouts was not affected (F). Asterisks indicate a significant difference (***p<0.001, 
****p<0.0001) from vehicle using a two-way repeated-measures ANOVA with 
Bonferroni’s correction for multiple comparisons. Data are shown as mean ± SEM. Data 
























































































































Figure 2.5: No Differences in Total Sleep or Wake in the Hour Prior to CNO or 
Vehicle Administration. Quantification of time spent in wake (A), NREM sleep (B), and 
REM sleep (C) in the hour preceding injection of vehicle or CNO as measured by 
EEG/EMG. A two-way repeated-measures ANOVA showed no differences in the 




























































Figure 2.6: No Differences in Sleep or Wake Architecture in the Hour Prior to CNO 
or Vehicle Administration. Quantification of average bout duration and number of 
bouts for wake (A & D), NREM (B & E), and REM (C & F) sleep in the hour prior to 
injection revealed no baseline differences between groups or recording days. Data were 




























































































































Figure 2.7: Chemogenetic Activation of POA Tac1 Neurons Increases Movement in 
an Open Field without Altering Open Field Place Preference. (A) Total ambulatory 
distance during the 20-minute recording session increased following administration of 
3mg/kg CNO only in hM3Dq-expressing mice. (B) Average speed was also increased in 
hM3Dq-expressing mice following CNO administration. (C) Schematic showing how 
behavioral place preference in the open field was determined. The percent time spent 
outside a center circle with a radius “r” from the center of the open field was calculated 
for hM3Dq-expressing (D), hM4Di-expressing (E), and control (F) mice following 
injection of vehicle or CNO. Regardless of how the center of the field was defined, there 
were no differences in place preference probability distributions between treatments for 
any group. Asterisks indicate a significant difference (****p<0.0001) from vehicle using a 
two-way repeated measures ANOVA with Bonferroni’s correction for multiple 
comparisons. Place preference probability distributions were compared using the 
Kolmogorov-Smirnov test. Data in (A) and (B) are shown as mean ± SEM. Solid lines 

































































































































Figure 2.8: POA Tac1 Neurons Project to Known Wake-Promoting Nuclei. hM3Dq-
mCherry-positive terminals were observed in the (A) LH, (B) TMN, (C) vPAG, (D) VTA, 
and (E) LC. Column 1 shows a low magnification image of each region, while columns 2-
4 show high-magnification views of the region outlined by white dashed box in column 1. 
Sections were stained for mCherry (red) as well as (A) orexin, (B) histidine 
decarboxylase, and (C-E) tyrosine hydroxylase, shown in cyan. Scale bar is 200um in 
column 1 and 50um in columns 2-4. Abbreviations: f, fornix; cp, cerebral peduncle; LH, 
lateral hypothalamus; Te, terete hypothalamic nucleus; TMN, tuberomammillary nucleus; 
aq, aqueduct; vPAG, ventral periaqueductal gray; ml, medial lemniscus; fr, fasciculus 
retroflexus; VTA, ventral tegmental area; RM, retromamillary nucleus; 4V, fourth 

















CHAPTER 3 – Activation of POA Tac1 Neurons Stabilizes the Wake State 
Over Volatile Anesthetic-Induced Unconsciousness 
Introduction 
Endogenous sleep and general anesthesia are distinct states that share similar traits. Of 
particular interest to neuroscience is the loss of consciousness that accompanies both 
states.  Multiple lines of evidence demonstrate that general anesthetics can coopt the 
neural circuits regulating arousal to produce unconsciousness.  However, controversy 
remains as to whether the neural circuits, and more specifically, the same neurons 
shaping sleep and wakefulness actually do influence the anesthetic state in vivo. Past 
work has demonstrated that the preoptic area of the hypothalamus (POA) is capable of 
modulating arousal in both natural (sleep and wake) (Gallopin et al., 2000; Lu et al., 
2000, 2002; McGinty and Szymusiak, 2001; Gong et al., 2004; Chung et al., 2017) as 
well as drug-induced (anesthetic-induced unconsciousness) states (Nelson et al., 2002; 
Lu et al., 2008; Li et al., 2009; Moore et al., 2012; Liu et al., 2013; Han et al., 2014; 
McCarren et al., 2014; Zhang et al., 2015a). However, the degree to which the same 
population of neurons within the POA modulates arousal in both sleep and anesthesia is 
unclear.  
This is due in large part to the molecular and functional heterogeneity of the POA (Moffitt 
et al., 2018), with sleep-active neurons existing alongside wake-active and arousal state-
indifferent neurons (Kaitin, 1984; Szymusiak and McGinty, 1986; Szymusiak et al., 1998; 
Takahashi et al., 2009). Previous work examining arousal state regulation under general 
anesthesia has largely focused on the role of two broad classes of POA neurons: the 
inhibitory GABAergic/galaninergic and excitatory glutamatergic neurons. However, these 
studies have produced sometimes-opposing results. For instance, isoflurane-induced 
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unconsciousness increases expression of c-Fos in and directly depolarizes putative 
sleep-active GABAergic neurons within the ventrolateral preoptic area (VLPO) (Moore et 
al., 2012), yet broad activation of this GABAergic population alters sleep-wake 
architecture (Saito et al., 2013; Kroeger et al., 2018) without affecting anesthetic 
induction or recovery time (Vanini et al., 2020). We hypothesized that the POA’s broad 
neuronal diversity could mask convergent roles of a subset of neurons in regulating both 
arousal and anesthesia, and that a more refined targeting of POA cell types is needed. 
Our previous results demonstrate that POA Tac1 neurons strongly promote wakefulness 
and are thus involved in arousal state regulation, yet the role of these POA Tac1 
neurons in modulating anesthetic states has not yet been examined. Thus, in this study 
we tested the hypothesis that increasing activity of POA Tac1 neurons, which is 
sufficient to promote and consolidate wakefulness at the expense of unconsciousness 
accompanying natural sleep would also rouse individuals from anesthetic-induced 
unconsciousness. Using righting reflex assays and video tracking, we show that Tac1 
activation confers partial resistance to both isoflurane- and sevoflurane-induced 
unconsciousness, providing additional evidence for the ability of natural sleep/wake 
nodes to also modulate responsiveness to general anesthesia.  
 
Results 
Activation of POA Tac1 neurons has no effect on body temperature 
As anesthetic sensitivity measures are dependent in part on core body temperature, the 
thermogenic potential of activating Tac1 POA neurons was measured.  In the absence of 
an anesthetic challenge, CNO treatment did not alter core body temperature (p=0.7651, 
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Figure 3.1). Similarly, with active warming during anesthetic exposure (Sun et al., 2006), 
core body temperature remained unchanged (36.9 ± 0.1°C prior to exposure and 37.2 ± 
0.1°C after exposure). These results confirm that any differences in anesthetic sensitivity 
observed after POA Tac1 activation are not a result of altered body temperature.  
Activation of POA Tac1 neurons increases ambulatory activity under isoflurane 
To begin to examine whether POA Tac1 activation is capable of modulating sensitivity to 
volatile anesthetics, locomotor activity was recorded and tracked under increasing 
concentrations of isoflurane in hM3Dq-expressing mice (n=10) and mCherry-expressing 
mice (n=10) after intraperitoneal administration of vehicle or 3mg/kg CNO. Prior to 
anesthetic delivery and vehicle/CNO administration, no differences in locomotion existed 
between groups (p=0.9382). However, hM3Dq mice given CNO exhibited significantly 
more locomotion, measured as distance traveled across the recording period, compared 
to vehicle at 0.3% isoflurane (p<0.0001; 37.21m ± 2.84m after CNO compared to 
10.93m ± 1.12m after vehicle) and 0.6% isoflurane (p<0.0001; 25.22m ± 2.05m after 
CNO compared to 8.94m ± 1.48m after vehicle) (Figure 3.2A & 3.2B). This increased 
resistance to the sedative and hypnotic actions of isoflurane was ultimately overcome by 
a higher 0.9% dose of isoflurane (p=0.3986), suggesting that POA Tac1 activation 
confers partial, but not absolute, resistance to isoflurane anesthesia. CNO did not alter 
locomotion at any dose compared to vehicle for the mCherry mice (p=0.7915 at 0.3%; 
p=0.9048 at 0.6%; p=0.4466 at 0.9%) (Figure 3.2B).  
Activation of POA Tac1 neurons stabilizes wakefulness against isoflurane on 
induction and emergence  
Sensitivity to isoflurane was assessed using the loss of righting reflex (LORR) assay 
(Sun et al., 2006). Population dose-response curves were generated for Tac1-Cre mice 
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expressing hM3Dq receptors (n=16 mice), hM4Di receptors (n=20 mice), or mCherry 
only (n=16 mice) on separate days either after intraperitoneal administration of vehicle or 
3mg/kg CNO. hM3Dq-expressing mice given CNO displayed increased resistance to 
isoflurane induction (Figure 3.3A) and an even more impressive ability to exit the 
anesthetic state and return to wakefulness during ongoing isoflurane exposure (Figure 
3.3B), illustrated by the rightward shift of both curves compared to vehicle. The mean 
induction EC50 dose, or dose at which half the population had lost the righting reflex, 
shifted from 0.77% (95% confidence interval [CI]: 0.75%-0.79%) after vehicle to 0.90% 
after CNO (CI: 0.89%-0.91%). The emergence EC50 dose, or dose at which half the 
population regained righting, increased from 0.39% (CI: 0.37%-0.42%) after vehicle to 
0.71% (CI: 0.70%-0.71%) after CNO. Just as POA Tac1 inhibition had no effect on sleep 
or arousal, it similarly did not alter sensitivity to isoflurane on either induction or 
emergence (induction EC50 shift from 0.81% [CI: 0.78%-0.84%] after vehicle to 0.82% 
[CI: 0.81%-0.83%] after CNO; emergence EC50 shift from 0.51% [CI: 0.47%-0.56%] after 
vehicle to 0.43% [CI: 0.39%-0.48%] after CNO). CNO had no effect on the isoflurane 
sensitivity of the control mCherry group (induction EC50 shift from 0.79% [CI: 0.74%-
0.83%] after vehicle to 0.82% [CI: 0.81%-0.83%] after CNO; emergence EC50 shift from 
0.44% [CI: 0.40%-0.48%] after vehicle to 0.50% [CI: 0.47%-0.52%] after CNO).  
Activation of POA Tac1 neurons stabilizes wakefulness against sevoflurane on 
induction 
As past work illustrates that anesthetics exert their effects at numerous, sometimes non-
overlapping, molecular targets as well as nuclei across the brain (Nelson et al., 2002, 
2003; Kelz et al., 2008; Lu et al., 2008; Gompf et al., 2009; Moore et al., 2012; Han et 
al., 2014), we also examined whether POA Tac1 neurons would modulate sensitivity to a 
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second inhaled anesthetic, sevoflurane.  Activation of POA Tac1 neurons (n=11 mice) 
significantly increased resistance to sevoflurane on emergence (Figure 3.4B), with the 
EC50 shifting from 1.25% (CI: 1.17%-1.32%) after vehicle to 1.63% (CI: 1.59%-1.67%) 
after CNO. While there was increased resistance to induction, this shift was not 
significant (EC50 shift from 1.70% [CI: 1.62%-1.77%] after vehicle to 1.81% [CI: 1.75%-
1.87%] after CNO, Figure 3.4A). Similar to the results observed with isoflurane, 
inhibition of POA Tac1 neurons (n=13 mice) did not alter sensitivity to sevoflurane on 
either induction or emergence (induction EC50 shift from 1.71% [CI: 1.67%-1.74%] after 
vehicle to 1.66% [CI: 1.60%-1.72%] after CNO; emergence EC50 shift from 1.22% [CI: 
1.15%-1.29%] after vehicle to 1.08% [CI: 0.97%-1.19%] after CNO, (Figure 3.4A and 
3.4B).  
Activation of POA Tac1 neurons promotes resistance during prolonged, steady-
state isoflurane anesthesia at both the population and individual level  
Dose-response assays allow for investigations into population-level anesthetic 
sensitivity, but examining responsiveness over a prolonged exposure to a steady 
concentration of anesthetic allows for comparisons of individual-based responses rather 
than population-based (McKinstry-Wu et al., 2019; Wasilczuk et al., 2020). This is 
especially important given that anesthetic sensitivity varies dramatically across 
individuals, potentially complicating population-based examinations of modulations in 
sensitivity (Wasilczuk et al., 2020). To examine how activation of POA Tac1 neurons 
modulates sensitivity to isoflurane on an individual level, we exposed mice to three hours 
of 0.6% isoflurane and assessed the presence or absence of the righting reflex after two 
hours of isoflurane in environmentally-controlled, warmed chambers that underwent one 
volume turnover per minute.  This ensured that brain anesthetic concentrations were at 
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steady state.  Righting reflex was tested every 3 minutes over 20 consecutive trials in 
hM3Dq-expressing mice (n=10) and mCherry control mice (n=10).  We compared the 
probability of righting in both groups when the mice were given CNO or vehicle in 
randomized order (Figure 3.5A). Plots of population sensitivity reiterated the dose-
response findings, showing that activation of POA Tac1 neurons increases the 
probability of righting compared to vehicle (Figure 3.5B). This increased resistance held 
at the individual level as well. Compared to vehicle, individual hM3Dq mice given CNO 
had a significantly greater probability of righting, which defines the waking state  
(p=0.0045; 62.6% ± 9.7% after CNO compared to 39.6% ± 12.6% after vehicle; Figure 
3.5D). No differences were observed on the population or individual level at steady state 
for mCherry mice (p>0.9999; Figure 3.5C & 3.5D) 
Exposure to a hypnotic dose of isoflurane has no effect on POA Tac1 c-Fos 
expression  
As an initial examination into isoflurane action on the POA Tac1 neurons, Tac1xAi6 mice 
were exposed to 3 hours of either 1.2% isoflurane or 100% oxygen, then sacrificed and 
sections containing the POA stained for c-Fos, a marker of antecedent neuronal activity. 
No significant differences in the number of c-Fos-expressing Tac1 neurons were 
detected between the isoflurane-exposed and oxygen-exposed mice (p=0.0910; Figure 
3.6A). This is unlikely to be the result of differences in counting areas, as no differences 
in total number of Tac1 neurons were detected either (p=0.8309; Figure 3.6A). To 
ensure no issues occurred during the anesthetic exposure that may have confounded 
our results, we examined c-Fos expression in two regions known to be activated by 
isoflurane: the VLPO and SON (Moore et al., 2012; Jiang-Xie et al., 2019). Our results 
recapitulated these findings, with significant increases in c-Fos in both regions (VLPO: 
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p=0.0073, 92.31 ± 10.75 neurons after isoflurane compared to 54.22 ± 3.63 after 
oxygen, Figure 3.6B; SON: p=0.0002, 103.3 ± 13.6 neurons after isoflurane compared 
to 22.99 ± 2.06 neurons after oxygen, Figure 3.6C), suggesting the anesthetic exposure 
occurred as anticipated.  
 
Discussion 
Here, we demonstrate that chemogenetic activation of POA Tac1 neurons biases 
towards the waking state over isoflurane- and sevoflurane-induced unconscious states. 
This increase in resistance is not due to modulations of body temperature. Following 
activation of POA Tac1 neurons, mice exit the anesthetic state at doses that would 
formerly have kept them anesthetized. Additionally, during prolonged exposure to a 
constant dose of isoflurane, arousal promoting effects of POA Tac1 activation occur not 
only in the population on average but in each individual as well.  The potent effects of 
Tac1 activation thus work to support the waking state over both endogenous as well as 
anesthetic-induced impairment of arousal. Chemogenetic inhibition of this population, 
while incomplete, did not affect arousal state, suggesting the POA Tac1 neurons are 
sufficient, but perhaps not necessary, for modulating anesthetic sensitivity and that this 
modulation may be caused via an independent pathway from that used by the 
anesthetics to produce hypnosis. 
In addition to regulating sleep/wake and anesthesia, the POA is also involved in 
regulating body temperature. Multiple studies have demonstrated the existence of 
neurons within the POA that regulate both sleep and body temperature, with activation of 
galaninergic VLPO neurons as well as glutamatergic MnPO and MPO neurons 
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promoting both sleep and a reduction of body temperature (Zhang et al., 2015b; Harding 
et al., 2018; Kroeger et al., 2018; Vanini et al., 2020). Activation of POA Tac1 neurons, 
in contrast, produced no changes in body temperature, suggesting this population is not 
shared between the circuits controlling sleep and body temperature and that our 
changes in anesthetic sensitivity were not due to a confounding change in body 
temperature. 
The enhanced locomotion observed under 0.3% and 0.6% isoflurane mirrors the 
enhanced locomotion observed in the open field testing in Chapter 2. As discussed in 
that chapter, tachykinins have been linked to locomotion in past studies. It is important to 
note that the increased locomotion was only observed at lower concentrations, and that 
ambulatory activity nearly ceased at the higher 0.9% dose after both CNO and vehicle. 
This suggests that POA Tac1 neurons are capable of destabilizing the anesthetic state 
and biasing the animal towards wake, but only when the brain is near the tipping point 
between responsiveness and unresponsiveness and not deeply anesthetized.  
POA Tac1 activation restored wakefulness during ongoing doses of isoflurane that 
produced unconsciousness in vehicle treated controls. Moreover, POA Tac1 activation 
also hindered the onset of isoflurane anesthesia, as shown in the population dose 
response curves. On the individual level, prolonged steady-state exposures revealed a 
similar increase in wakefulness after POA Tac1 activation compared to vehicle. CNO 
administration increased the probability of righting in all mice compared to vehicle, 
confirming that the increased resistance observed on the population level is not due to a 
small group of mice driving the effect, but is instead reflective of each individual.  
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In addition to comparisons of overall resistance to anesthetics, these prolonged steady-
state exposures also allow an examination into state transition dynamics under 
anesthesia. Previous work has shown that stochastic fluctuations between responsive 
and unresponsive arousal states occur even under a constant anesthetic dose, and that 
these fluctuations exhibit a resistance to state transitions that is independent of 
anesthetic potency (Wasilczuk et al., 2020). Preliminary data shows an increase in state 
transition probability after POA Tac1 activation (Figure 3.7A) along with an increase in 
estimated noise (Figure 3.7B), which has previously been shown to be associated with 
increased frequency of state transitions (Wasilczuk et al., 2020). Furthermore, POA 
Tac1 activation reduces the probability of remaining unresponsive and increases the 
probability of remaining responsive compared to vehicle (Figure 3.7C & 3.7D). However, 
a caveat for this preliminary data is that the increased resistance caused by POA Tac1 
activation means that the same isoflurane concentration (0.6%) is no longer equipotent 
between the CNO and vehicle groups. This confound prevents a proper comparison into 
the potential differences in state transition probability. Thus, any differences in the 
probability of remaining unresponsive may be due to the differences in potency rather 
than independent effects on state transition dynamics. In order to accurately examine 
whether POA Tac1 activation modulates these state transition dynamics, equipotent 
doses must be compared. Future work is required to measure righting reflex after CNO 
at an anesthetic potency that is equivalent to the vehicle potency at 0.6%.  
In addition to increasing resistance to isoflurane, POA Tac1 activation also enhanced 
wakefulness during doses of sevoflurane that produced unconsciousness in vehicle 
treated controls. POA Tac1 activation did produce a rightward shift on sevoflurane 
induction, though the shift did not reach significance. One potential explanation is that 
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due to the smaller number of mice examined under sevoflurane compared to isoflurane, 
we were simply underpowered to detect a difference on induction. Alternatively, the lack 
of a significant shift on induction may be due to sevoflurane’s faster rate of uptake 
compared to isoflurane, resulting from sevoflurane’s lower blood/gas partition coefficient. 
A faster induction of sevoflurane anesthesia may ultimately have minimized the 
experimental window available to detect a shift in resistance.  The unquestionable large 
and common effect of POA Tac1 activation facilitating emergence from two general 
anesthetics with a potential agent-specific differential effect on induction could also be 
indicative of a differential neurobiology for entering and exiting states of anesthesia (Kelz 
et al., 2008). State transition dynamics at steady state sevoflurane were not examined, 
but will be an important next step given past work establishing that the degree of 
resistance to state transitions differ between equipotent doses of isoflurane and 
sevoflurane (Wasilczuk et al., 2020).  
Finally, our results showing no significant decrease in c-Fos expression in the POA Tac1 
neurons following exposure to 1.2% isoflurane suggests that inhibition of these neurons 
under isoflurane does not occur and is therefore not required for isoflurane-induced 
hypnosis. This result, together with the lack of effect of inhibition, suggests that these 
POA Tac1 neurons promote wakefulness against anesthesia via a pathway that is 
independent of that used by the anesthetic.  
There are important considerations to take into account when interpreting these results, 
however. First is the relatively low level of c-Fos expression during oxygen exposure 
(~10% of Tac1 neurons also expressed c-Fos). This low basal level of expression may 
make it difficult to detect significant decreases in c-Fos expression induced by isoflurane 
exposure, especially given the small number of animals (n=6) per group. Additionally, c-
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Fos expression is not capable of reflecting changes in neuronal activity on a shorter 
timescale. It is therefore possible that POA Tac1 neuronal activity is affected by 
isoflurane, but on a timescale that is incompatible with c-Fos protein induction. Finally, 
our dose-response results suggest a stronger role for POA Tac1 neurons in emergence 
from anesthesia compared to induction. The isoflurane exposure paradigm used here 
only reflects activity during prolonged maintenance of the anesthetic state, not induction 
or emergence. Therefore, while these results suggest POA Tac1 neuronal activity is not 
significantly modulated by isoflurane, more accurate investigations into POA Tac1 
activity under isoflurane is necessary, specifically with methods that can detect 
differences in activity on a faster timescale, such as GCaMP. 
These results support an ability of POA Tac1 neurons to promote wakefulness over 
volatile anesthetic-induced hypnosis, though the lack of effect of inhibition and no 
significant alterations in c-Fos levels after exposure to isoflurane suggest that this is 
through an independent pathway parallel to that used by the anesthetics to generate 
unconsciousness. As mentioned earlier however, more work is needed to conclusively 
determine whether anesthetics modulate the activity of this neuronal population.  
Our results mirror findings in other arousal-promoting regions, where activation prompts 
an exit from the anesthetic state. For example, chemogenetic activation of noradrenergic 
LC neurons produces cortical EEG activation under continuous isoflurane anesthesia, 
delays induction of isoflurane hypnosis, and accelerates emergence from isoflurane 
hypnosis (Vazey and Aston-Jones, 2014). Similarly, cholinergic stimulation of the 
prefrontal cortex restores wake-like EEG and behavior under continuous sevoflurane 
exposure (Pal et al., 2018) and optogenetic activation of dopaminergic VTA neurons 
during continuous isoflurane exposure produces EEG arousal and restores righting 
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reflex (Taylor et al., 2016). Further identification of the hypothalamic microcircuitry 
regulating sleep and wakefulness with the ability to impact drug-induced states of 
unconsciousness is needed, including additional examinations of the exact role of the 
POA Tac1 neurons in both natural and anesthetic arousal state regulation. 
 
Materials and Methods 
Mice  
Studies were approved by the Institutional Animal Care and Use Committee at the 
University of Pennsylvania and were conducted in accordance with National Institutes of 
Health guidelines. Chemogenetic experiments were performed in male and female Tac1-
IRES-Cre mice (Jackson Laboratories, stock 021877) aged 10-18 weeks, weighing 18-
25g at the time of surgery. Immunohistochemistry experiments involving c-Fos were 
performed in male and female Tac1-IRES-Cre mice crossed to an Ai6-ZsGreen1 
reporter line (Jackson Laboratories, stock 007906), aged 10-16 weeks, weighing 18-25g 
at time of anesthetic exposure. Male and female mice were distributed equally across 
groups in each experiment. Littermates were split between experimental and control 
groups while also ensuring equal distribution of males and females between groups. All 
mice were housed on a reverse 12h:12h light/dark cycle (ZT0/lights on 7:00pm) with ad 
libitum access to food and water.  
Viral Vectors and Chemicals 
Cre-dependent adeno-associated viral vectors (AAV8-hSyn-DIO-hM3Dq-mCherry, 
Addgene, 44361; AAV8-hSyn-DIO-hM4Di-mCherry, Addgene, 44362) were used to 
selectively express excitatory hM3Dq or inhibitory hM4Di receptors in Tac1 hypothalamic 
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neurons. Control animals received a Cre-dependent adeno-associated viral vector 
containing mCherry only (AAV8-hSyn-DIO-mCherry, Addgene, 50459). Clozapine-N-
oxide (CNO, Sigma-Aldrich) was prepared fresh for each experiment by dissolving in 
sterile saline to a concentration of 0.3mg/ml. CNO dosing for all experiments was 
3mg/kg. Injection volumes were constant between vehicle and CNO for each animal, 
and injection order was randomized for all experiments.  
Surgical Procedures 
Mice were anesthetized with 2.5% isoflurane in 100% oxygen for induction, and 
maintained on 1.5% isoflurane for the remainder of the surgery. After lack of response to 
a toe pinch, mice were placed on a stereotaxic frame (Kopf Model 902). Eyes were 
protected by an eye ointment and core temperature was maintained at 37±0.5°C using a 
closed-loop heating pad (CWE Inc). To target the POA, mice received bilateral 300nl 
microinjections of virus delivered using a 33G, 10ul Hamilton syringe (Hamilton 
Company, 80008) mounted on a stereotaxic microinjection syringe pump (Stoelting Co). 
The injection coordinates relative to bregma were: AP -0.10mm; ML ±0.70mm; DV -
5.70mm. Following injection, the syringe was held in position for 10 minutes to avoid 
virus reflux up the syringe tract (Cardin et al., 2010). Following bilateral injections, the 
incision was sutured closed, isoflurane was discontinued, and animals received	0.5mg 
cefazolin and 0.125mg meloxicam to maintain analgesia. All mice were allowed to 
recover for a minimum of two weeks prior to the start of habituation. 
Body Temperature Measurement 
Body temperature was measured rectally using a digital thermometer (Fisherbrand 15-
078-187). Temperatures were taken prior to an i.p. injection of 3mg/kg CNO, then 
repeated 1 hour and 2 hours post-injection. Temperatures were also measured and 
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recorded immediately before and after isoflurane righting reflex assessment to ensure 
adequate heating from the water bath.  
Isoflurane exposure for c-Fos induction  
All mice were habituated to sealed, temperature-controlled, 200mL cylindrical chambers 
with 100% oxygen flowing at 200mL/minute, as previously described (Sun et al., 2006). 
On the experimental day, mice were exposed to 3 hours of either 100% oxygen or 1.2% 
isoflurane vaporized in 100% oxygen. Throughout the exposure, chamber isoflurane 
concentrations were confirmed using a Riken FI-21 refractometer (AM Bickford, NY). 
After 3 hours, mice were immediately transcardially perfused with ice-cold PBS followed 
by 4% paraformaldehyde. Brains were then removed and post-fixed in 4% 
paraformaldehyde overnight. 
Immunohistochemistry for c-Fos 
Following overnight post-fixation in 4% paraformaldehyde, brain tissue was sectioned via 
compresstome (Precisionary Instruments) at 40µm and standard c-Fos 
immunohistochemistry was performed on sections containing the hypothalamus. 
Sections were permeabilized and blocked in 2.5% normal goat serum in PBST (2% 
TritonX-100 in PBS) for 1 hour at room temperature, followed by an overnight incubation 
at 4° C in rabbit anti-cFos primary antibody (Cell Signaling Technologies, 1:1000). 
Sections were then washed in PBS, followed by a 2 hour incubation with Alexa Fluor 488 
goat anti-rabbit secondary antibody (ThermoFisher, 1:200). Following a final wash in 
PBS, sections were mounted and cover slipped with mounting medium containing a 
DAPI counterstain (Vector Laboratories).  
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Imaging and Cell Counting 
Sections used for c-Fos counting were imaged at 20x using a confocal microscope 
(SP5II, Leica Microsystems). Counting was performed using ImageJ (Schindelin et al., 
2012) and conducted by a blinded experimenter. Only mice that displayed mCherry 
expression in the POA were included in analysis. The fraction of ZsGreen-positive 
neurons also positive for c-Fos were quantified for each 40um section, and subsequently 
averaged for each animal. Imaging for injection localization was performed using 
epifluorescence microscopy (Olympus BX41).  
Video Tracking 
Mice were placed in a gas-tight, temperature-controlled 2L chamber divided into 3 equal 
compartments to allow 3 mice to be recorded simultaneously. Activity was recorded by a 
video camera mounted overhead. To assess any differences at baseline, mice were 
recorded for 30 minutes with 100% oxygen prior to administration of vehicle or CNO. At 
the end of this period, mice received i.p. injections of 3mg/kg CNO or vehicle. 20 
minutes after injection, isoflurane was increased to 0.30%. Once the chamber had 
stabilized at that dose, video was again recorded for 30 minutes. This process was 
repeated twice, stepping up to 0.60% and 0.90% isoflurane. At each step, chamber 
concentration was confirmed using a Riken FI-21 refractometer (AM Bickford, NY). 
Injection order was randomized and trials were separated by at least 48 hours. 
Movement was tracked offline using custom Matlab software previously described 
(Wasilczuk et al., 2018), and total distance traveled across each 30 minute period was 
quantified.  
Righting Reflex Assessment for Dose Response 
All mice were habituated to gas-tight, temperature-controlled, 200mL cylindrical 
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chambers with 100% oxygen flowing at 200mL/minute, as previously described (Sun et 
al., 2006). As previously shown, this flow rate results in chamber equilibration within 5 
minutes (McKinstry-Wu et al., 2019). Mice underwent staircase increasing followed by 
decreasing exposure to isoflurane or sevoflurane in a heated water bath with 15 minutes 
spent at each step.  To control for the duration of CNO efficacy, full dose response 
curves were generated across two separate sessions.  On the first testing day, 
isoflurane was increased from 0.0% to 1.2% (for induction) and then subsequently 
decreased back to 0.0% (for emergence) in 0.2% steps. At least 48 hours after the first 
testing day, the same group of mice was again exposed to the isoflurane staircase, but 
using odd concentrations (0.1%, 0.3%, and so on, with the final step remaining at 1.2%). 
The same two-session staircase protocol was used for sevoflurane, though the minimum 
and maximum concentrations were changed from 0.0% and 1.2% to 0.9% and 2.4% due 
to sevoflurane’s lower anesthetic potency. Chamber concentrations were confirmed 
using a Riken FI-21 refractometer (AM Bickford). After 15 minutes at each concentration 
to ensure both chamber and brain equilibration, righting reflex was assessed for each 
animal. An animal was considered to have an intact righting reflex if it successfully 
returned to a prone position twice in a row. Otherwise, the righting reflex was considered 
to be absent.   
Righting Reflex Assessment for Steady State Doses 
All mice were habituated to sealed, temperature-controlled chambers as described 
above. Mice were then exposed to 0.60% isoflurane in 100% oxygen for 3 hours, 
beginning at ZT13. In the last hour of the exposure, the presence or absence of the 
righting reflex (RR) was checked every 3 min, giving a total of 20 RR assessments per 
mouse per exposure. Each mouse was exposed to 0.60% isoflurane a total of 4 times 
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over the course of 2 weeks. Chamber isoflurane concentrations in all assays were 
confirmed using a Riken FI-21 refractometer (AM Bickford, NY.).  
Transition Probability Estimation 
The probability of transition between unresponsive (U) and responsive (R) states during 
steady state isoflurane anesthesia was calculated as previously described (Wasilczuk et 
al., 2020). Briefly, the probability of the U or R state was modeled using the following 
Markov matrix consisting of four conditional probabilities P(It|Jt-1) that reflect the 
probability that an animal is in state I (responsive or unresponsive) given that it was in 
state J (responsive or unresponsive) on the previous trial, with the sum of conditional 





These conditional probabilities were estimated for each individual animal and compared 
between vehicle and CNO conditions for each group. 
Quantification and Statistical Analysis 
Data were analyzed using Matlab 2019b (Mathworks, MA) using the Statistics and 
Machine Learning Toolbox and Prism v8.0 (GraphPad Software Inc). All data collection 
was randomized and counter-balanced. All data were tested for normality and are 
reported as mean ± standard error of the mean. A p value <0.05 was considered 
statistically significant for all comparisons. Behavioral changes as a function of virus 
(hM3Dq-mCherry, hM4Di-mCherry, or mCherry) and treatment (vehicle or CNO) were 
evaluated using a two-way repeated-measures ANOVA followed by Bonferroni’s 
correction for multiple comparisons. The percentage of active cells (c-Fos+) after 
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exposure to 1.2% isoflurane or 100% oxygen was compared using a two-tailed unpaired 
t test.  Isoflurane and sevoflurane dose response curves were generated by nonlinear 
regression fitting of the population responsiveness at each concentration collectively to 
the hill equation. Induction and emergence arms were computed separately for each 
condition. Parameter estimates and confidence intervals were computed using the 
Jacobian of the nonlinear regression model. Indications of significance are as follows: 


























Figure 3.1: Chemogenetic Activation of POA Tac1 Neurons Has No Effect on Body 
Temperature. Core body temperature measured prior to administration of 3mg/kg CNO 
and again at 1 and 2 hours post-injection showed no significant differences in either 
hM3Dq-expressing mice or their control counterparts, as determined by a two-way 










Figure 3.2: Activation of POA Tac1 Neurons Increases Ambulatory Activity Under 
Isoflurane. (A) Data from a representative hM3Dq-expressing mouse showing distance 
traveled per second plotted over a 30-minute trial at increasing concentrations of 
isoflurane. Baseline recording occurred in the 30 minutes immediately prior to CNO or 
vehicle administration. Both vehicle and CNO are from the same animal.  (B) Total 
distance traveled over each 30-minute trial shown for each concentration of isoflurane. 
CNO significantly increased distance traveled at 0.3% and 0.6% isoflurane, but not at 
0.9% in hM3Dq-expressing mice (n=10). CNO had no effect on control mCherry mice 
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(n=10). Asterisks indicate a significant difference (**p<0.01, ****p<0.0001) from vehicle 
















Figure 3.3: Chemogenetic Activation of POA Tac1 Neurons Restores Wakefulness 
Against Isoflurane. Dose response curves showing the fraction of unconscious mice as 
judged by a loss of righting reflex in response to stepwise increases or decreases in 
anesthetic concentration. For both induction (A) and emergence (B), administration of 
3mg/kg CNO to hM3Dq-expressing mice increased resistance to isoflurane, shifting the 
dose response curve (dotted blue line) to the right of controls. POA Tac1 inhibition 
(dotted purple lines) did not affect sensitivity to either anesthetic. Horizontal axes are 
displayed on a logarithmic scale. Best-fit sigmoidal dose-response curves are shown 








Figure 3.4: Chemogenetic Activation of POA Tac1 Neurons Restores Wakefulness 
Against Sevoflurane. Dose response curves showing the fraction of unconscious mice 
as judged by a loss of righting reflex in response to stepwise increases or decreases in 
anesthetic concentration. Administration of 3mg/kg CNO to hM3Dq mice (blue dotted 
lines) increased resistance to sevoflurane on induction (A) but not emergence (B). POA 
Tac1 inhibition (dotted purple lines) did not affect sensitivity to sevoflurane. Horizontal 
axes are displayed on a logarithmic scale. Best-fit sigmoidal dose-response curves are 








Figure 3.5: Activation of POA Tac1 Neurons Promotes Resistance During 
Prolonged, Steady-State Isoflurane Anesthesia. (A) Schematic showing how righting 
reflex was assessed. Mice that returned to a prone position after being placed in a 
supine position were classified as “responsive”, while mice that failed to right themselves 
were considered “unresponsive”. Mice were brought to 0.6% isoflurane and held at that 
concentration for 3 hours. During the final hour, righting reflex was assessed every 3 
minutes. (B) Probability of righting at the population level increased after CNO 
administration in hM3Dq-expressing mice (n=10). Each dot represents the fraction of the 
population found to be responsive at each trial. (C) No differences in population 
probability of righting were observed between vehicle and CNO in controls (n=10). (D) 
Probability of righting was increased at the individual level as well, with every hM3Dq-
expressing mouse experiencing an increased probability of righting after CNO compared 
to vehicle. No differences were observed in controls. Each individual’s probability of 
righting was averaged over all righting reflex assessments. Asterisks indicate a 
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significant difference (**p<0.01) from vehicle using a two-way repeated measures 




























Figure 3.6: Exposure to 1.2% Isoflurane Has No Effect on POA Tac1 c-Fos 
Expression. (A) Mice exposed to 3 hours of 1.2% isoflurane or 100% oxygen showed 
no significant differences in total number of Tac1 neurons also positive for c-Fos. 
Additionally, the proportion of all Tac1 neurons that also expressed c-Fos was not 
statistically significant between conditions. Red dashed box highlights the area included 
in counts. (B & C) c-Fos expression in VLPO (B) and the supraoptic nucleus (C), two 
regions known to be activated by isoflurane, was indeed significantly increased in 
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isoflurane-exposed animals, confirming the anesthetic exposure was successful. Red 
boxes indicate the region in the microscopy images, while white dashed boxes indicate 
area included in counts. Asterisks indicate a significant difference (**p<0.01, ***p<0.001) 


























Figure 3.7: Activation of POA Tac1 neurons increases the probability of transition 
under steady state isoflurane. Preliminary data of state transition dynamics under 
steady state isoflurane show (A) Administration of 3mg/kg CNO increases the probability 
of state transition in hM3Dq mice compared to vehicle. (B) CNO also increases 
estimated noise in hM3Dq-expressing mice. (C) CNO decreases the probability of 
remaining unresponsive following a previous unresponsive trial compared to vehicle and 
(D) increases the probability of remaining responsive following a previous responsive 





CHAPTER 4 – General Discussion 
 
The ability of the brain to regulate arousal states has been the topic of many 
investigations for nearly a century. While much has been learned about the endogenous 
neural circuits that regulate sleep and wake, newly recognized brain regions with the 
ability to modulate arousal state continue to be discovered, emphasizing our incomplete 
understanding of this crucial regulatory circuitry. Particularly in the POA, investigations 
are plagued by the molecular and functional heterogeneity of the region, making a full 
understanding of its role in arousal state regulation difficult. Failure to properly regulate 
arousal state can have serious costs, including increased risk of obesity, cardiovascular 
disease, and impaired cognition from improper sleep/wake regulation, and intraoperative 
awareness or delayed emergence from anesthesia. Given these consequences of 
improper arousal state regulation — both in natural sleep/wake and in response to 
general anesthesia — untangling the circuits by which the brain coordinates arousal 
state is critical.  
The studies in this dissertation were motivated by the hypothesis that the GABAergic 
and glutamatergic markers used in past examinations of the POA are not be specific 
enough to distinguish sleep-promoting POA neurons from the wake-promoting 
population. Research implicating neuropeptides, particularly tachykinins, in sleep and 
wake regulation led us to hypothesize that Tac1 may be a more accurate marker of 
arousal state regulating neurons in the region. Furthermore, a number of studies have 
implicated sleep- and wake-regulating brain areas in anesthetic hypnosis, yet evidence 
in the POA has been unclear. While some studies show that isoflurane activates 
GABAergic VLPO neurons, and lesioning these neurons produces acute resistance to 
isoflurane (Moore et al., 2012; Han et al., 2014), others show that chemogenetic 
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activation of GABAergic VLPO neurons alters sleep-wake architecture without affecting 
anesthetic sensitivity or recovery time (Eikermann et al., 2011; Vanini et al., 2020). 
Again, we hypothesized that use of such a broad molecular marker may mask a subset 
of POA neurons capable of modulating both spontaneous and anesthetic-induced 
changes in arousal.  
Our results confirm a role for POA Tac1 neurons in arousal state regulation. In Chapter 
2, we show that chemogenetic activation of POA Tac1 neurons strongly promotes and 
consolidates wakefulness over natural sleep. Activation of these neurons also promotes 
locomotor activity that is unrelated to anxiety. In Chapter 3, we show that activation of 
these same wake-promoting neurons also enhances resistance to isoflurane and 
sevoflurane anesthesia, particularly on emergence from the anesthetic state. 
Furthermore, activation of POA Tac1 neurons increases resistance at the level of the 
population and the individual during prolonged exposure to a constant dose of 
isoflurane. The potent effects of Tac1 activation thus work to support the waking state 
over both endogenous as well as anesthetic-induced impairment of arousal. In the 
remainder of this chapter, I will summarize our key findings as well as discuss potential 
implications and future extensions of this body of work.  
 
Activation of POA Tac1 neurons promotes and consolidates wakefulness 
Contrary to previously published results (Chung et al., 2017), we found that 
chemogenetic activation of POA Tac1 neurons stabilizes the wake state, obliterating 
NREM and REM sleep even during periods of high circadian sleep pressure. As 
discussed in Chapter 2, there are a few potential explanations for the discrepancies in 
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our results, including viral transfection area and variable inhibition resulting from 
inhibitory DREADDs. Molecular profiling of the POA shows that Tac1 is co-expressed 
with both GABA and glutamate (Moffitt et al., 2018), illustrating that even more selective 
neuropeptide markers may be inadequate to conclusively distinguish sleep- from wake-
promoting neuronal populations within the POA. These contrasting results mirror the 
variable results of exogenous tachykinin administration, which promotes wakefulness 
when applied to the LC (Guyenet and Aghajanian, 1977) but promotes sleep when 
applied to the VLPO (Zhang et al., 2004).  
Together, this suggests that a single molecular marker may not be sufficient to 
accurately distinguish sleep and wake population within the POA. Molecular markers 
combined with projection-specific labeling may be one method to more accurately 
identify these populations, as past work has shown that optogenetic activation of 
GABAergic POA neuronal cell bodies produces wake, while activation of only the 
GABAergic POA terminals in the TMN produces sleep (Chung et al., 2017). In Chapter 
2, we identified numerous potential targets of the POA Tac1 neurons, including the TMN, 
VTA, LH, vPAG, and LC. Investigations into projection-specific activation will also help to 
determine the pathway through which these POA Tac1 neurons exert their wake- and 
locomotion-promoting effects.  
 
Activation of POA Tac1 neurons promotes arousal over volatile anesthetic-induced 
hypnosis 
Our results in Chapter 3 demonstrate that activation of POA Tac1 neurons enhances 
resistance to isoflurane and sevoflurane anesthesia, particularly on emergence. 
94	
	
Furthermore, POA Tac1 activation promotes resistance throughout a prolonged 
exposure to a constant dose of isoflurane on both the population and individual level. 
Together, these results suggest that this population of neurons is capable of modulating 
arousal states under both natural sleep and wake and volatile anesthesia. Our findings 
are similar to investigations of other arousal promoting regions, such as the LC, PFC, 
and VTA, that demonstrate enhanced arousal under anesthesia in response to activation 
of these populations (Vazey and Aston-Jones, 2014; Taylor et al., 2016; Pal et al., 
2018).  
However, as noted in Chapter 3, our results fail to confirm that volatile anesthetics 
produce hypnosis via inhibition of this wake-promoting population. The inhibitory 
DREADD results show no effect of inhibition on anesthetic sensitivity. Furthermore, our 
results demonstrate no significant change in c-Fos expression in the POA Tac1 neurons 
following isoflurane exposure. Together, these suggest that while activation of this 
population may be sufficient to induce arousal, anesthetics likely produce hypnosis via a 
pathway that does not directly involve the POA Tac1 neurons. The data suggests that 
the arousal-promoting effects against anesthesia likely occur via an independent 
pathway than that used by the anesthetic to produce hypnosis. However, there are 
important limitations to consider when interpreting the c-Fos data, as discussed in the 
following section.  
This sufficiency to modulate anesthetic sensitivity without being required for anesthetic 
hypnosis is a common theme with many sleep- or wake-promoting nodes, emphasizing 
the differences between sleep and anesthetic-induced unconsciousness. Modulating the 
activity of any one arousal-regulating region can significantly alter sensitivity to 
anesthesia, but does not completely produce or prevent hypnosis on its own. Thus, there 
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is still much to understand about the mechanisms by which anesthetics exert their 
hypnotic effects and to what degree this involves the endogenous sleep and arousal 
circuitry. Just as with regulation of sleep and wake, our results emphasize that an 
understanding of anesthetic hypnosis must take into consideration neural circuits as a 
whole, rather than individual nodes. 
POA Tac1 activation promotes resistance to both isoflurane and sevoflurane on 
emergence much more strongly than on induction. There are two potential explanations 
for this finding. The first is due to methodological limitations. Anesthetic induction may 
have occurred on a timescale that was too rapid for differences to be detected by our 
frequency of righting reflex testing compared to emergence. Alternatively, our results 
may reflect distinct neural processes for induction and emergence, and emphasize a 
stronger role for the POA Tac1 neurons in the emergence process.  This supports 
previous work demonstrating hysteresis between induction and emergence for many 
anesthetics that suggests different mechanisms underlying each process (Friedman et 
al., 2010).  
Our POA Tac1 results would not be the first instance of a role for wake-promoting 
neurons in emergence from anesthetic hypnosis but little to not role in induction. 
Activation of wake-promoting PB neurons shortens time to emerge from both propofol 
and isoflurane anesthesia (Luo et al., 2018). Additionally, inhibition of sleep-promoting 
SON neurons has no effect on isoflurane induction, but does decrease time to emerge 
(Jiang-Xie et al., 2019). Finally, inhibition of wake-promoting orexinergic LH neurons has 
no effect on induction but delays emergence from both isoflurane and sevoflurane (Kelz 
et al., 2008). However, as mentioned in Chapter 3, the lack of induction effect for 
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sevoflurane may be the result of its lower blood/gas coefficient and subsequent faster 
rate of uptake, minimizing the window available to detect a change in induction.  
 
Limitations 
While the results presented here add important evidence to the growing body of 
literature that supports a role for the POA in wake-promotion, there are a few important 
limitations and considerations to discuss. One important consideration to take into 
account when studying arousal-promoting areas is whether the arousal promotion is a 
primary effect, or secondary to another, more specific pathway. Indeed, many wake-
promoting areas influence attention, reward, mood, and other behaviors that may explain 
their wake-promoting effects. Given the increased locomotion observed after POA Tac1 
activation in Chapter 2, we must consider the possibility that these POA Tac1 neurons 
are primarily locomotion-promoting, with wake promotion as a secondary effect that is 
necessarily tied to the enhanced locomotion.  
Another potential primary effect of POA Tac1 activation is activation of a pain-sensing 
pathway. Pain-activated primary sensory neurons release neuropeptides, including 
substance P and neurokinin α, into the dorsal horn of the spinal cord. These tachykinins 
and other neuropeptides activate NK1 receptors on spinal neurons that transmit pain, 
resulting in the sensation of pain (Steinhoff et al., 2014). Additionally, global deletion of 
the Tac1 gene reduces moderate to intense pain in mice (Cao et al., 1998), and 
pretreatment with an NK1 receptor antagonist reduced postsurgical pain in human 
patients following tooth extraction compared to placebo (Dionne et al., 1998), suggesting 
that release of tachykinins in selective areas are intimately involved in modulating the 
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sensation of pain. To our knowledge, the involvement of a hypothalamic source of 
tachykinins in pain has yet to be examined. 
However, pain is known to increase arousal over natural sleep as well as anesthetic-
induced unconsciousness. Pain and sleep are thought to share a reciprocal relationship, 
with changes in one affecting the other. Persistent pain increases wakefulness and 
reduces sleep in rodents, cats, and humans (Carli et al., 1987; Asplund, 1996; Guevara-
López et al., 2009). Conversely, disturbances in sleep reduce pain thresholds and 
predict future pain sensitivity (Finan et al., 2013). With respect to anesthetic hypnosis, 
epidural administration of local anesthetics reduces the dose of general anesthetic 
required to maintain an appropriate depth of anesthesia (Tverskoy et al., 1996; Hodgson 
and Liu, 2001), while patients without the combination of epidural anesthesia on top of 
an inhaled anesthetic showed evidence of arousal after incision compared to patients 
that also received epidural anesthesia (Kiyama and Takeda, 1997).  
Though we did not formally examine pain responses following POA Tac1 activation, we 
did not observe any obvious nocifensive behaviors. However, given the known 
involvement of tachykinins in modulating pain, and the role of pain in increasing arousal 
over both sleep and anesthesia, more testing is required to fully rule out an enhanced 
pain response as a cause of the increased wakefulness. Future work examining the 
firing activity of these POA Tac1 neurons across the sleep-wake cycle, during various 
waking behaviors, and in response to a variety of stimuli, including noxious ones, is 
needed to better understand their role in arousal regulation.  
Another limitation is that we did not functionally confirm the projections of POA Tac1 
neurons to the multiple wake-promoting regions discussed in Chapter 2. While evidence 
98	
	
of fibers in these areas is promising, more work is needed to confirm that these are 
functional synapses. The use of methodology such as channelrhodopsin-assisted circuit 
mapping (Petreanu et al., 2007) in future studies will help to confirm that these synapses 
are functional and allow us to distinguish which projection targets are causally involved 
in mediating the enhanced wakefulness we observe following POA Tac1 activation.  
Finally, limitations with the use of c-Fos as a marker of previous neuronal activity as well 
as incomplete inhibition by the hM4Di DREADDs prevent us from confidently concluding 
that POA Tac1 neurons are not causally involved in producing anesthetic hypnosis. Our 
DREADD results show a 30% decrease in neuronal activation following CNO 
administration to hM4Di-expressing mice. This may not have been a complete enough 
inhibition to alter arousal state, as 70% of the transfected neurons appear to still be 
active. A method that offers more effective silencing of neuronal activity, such as an 
optogenetic approach using halorhodopsin or archaerhodopsin, will help to clarify 
whether inhibition of POA Tac1 neurons is also capable of modulating arousal state. 
Our results showing that isoflurane exposure does not significantly decrease c-Fos 
expression in POA Tac1 neurons suggests that inhibition of this population is not 
required for anesthetic hypnosis. However, c-Fos does not offer a temporally specific 
reflection of neuronal activity, so it is possible that isoflurane does in fact modulate POA 
Tac1 activity, but on a timescale that is not captured with c-Fos. Additionally, c-Fos does 
not allow for an investigation of POA Tac1 neuronal activity during emergence from 
isoflurane, which is where the largest effect on arousal state occurs according to the 
dose-response data for both isoflurane and sevoflurane. Methods such as GCaMP, in 
vivo electrode recordings, and ex vivo patch recordings of POA Tac1 neurons will help 
clarify the effects of anesthetic action on these neurons. It will be especially interesting to 
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record POA Tac1 neuronal activity during unperturbed induction and emergence from 
anesthesia to better understand their role in each process outside of artificial 
chemogenetic activation.  More temporally precise methods of neuronal activation, such 
as optogenetics, will also allow for more specific examinations into POA Tac1 
modulation of anesthetic hypnosis on induction and emergence 
 
Conclusions and Future Directions 
The work presented here demonstrates that POA Tac1 neurons promote arousal over 
both natural sleep and volatile anesthetic hypnosis, and identifies multiple pathways for 
future examinations into their arousal-promoting role. Similar to understanding their role 
in natural arousal state regulation, examinations of POA Tac1 neuronal activity during 
induction, maintenance, and emergence from anesthesia will be critical in order to 
untangle the role they play in anesthetic hypnosis. As mentioned earlier, methods such 
as GCaMP, in vivo electrode recordings, and ex vivo patch recordings of POA Tac1 
neurons will aid in a more complete understanding of how anesthetics act on these 
neurons and potentially alter their activity. 
These results advance our understanding of arousal state-regulation by the POA, though 
there is still so much to learn. With the rapid development and utilization of new 
methodologies in neuroscience, it is becoming increasingly possible to classify and 
distinguish the molecular identities and connectivity of neurons involved in arousal state 
regulation. Methods such as channelrhodopsin-assisted circuit mapping, GCaMP 
calcium indicators, and single cell RNA sequencing present exciting opportunities to 
build on the work in this dissertation. Ultimately, a deeper understanding of the 
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molecular and functional makeup of the POA will be critical for unraveling how this 
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